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CHAPTER 1 
 
INTRODUCTION
1
 
 
The visual system and degenerative diseases of the central nervous system 
 
 One particular difficulty of studying components of the mammalian central nervous 
system (CNS) in vivo is the relative inaccessibility of the neural tissue. The CNS consists of the 
brain and spinal cord, which work together to process and integrate information from the 
environment and to exert control over an organism’s interactions with that environment. The 
brain is encased in a protective cavity formed by the bony neurocranium, while the spinal cord is 
housed within a protective bony structure known as the vertebral column. Such protective 
structures help minimize trauma to the vertebrate CNS; however, these same structures are a 
hindrance to experimental manipulation and imaging of the CNS in vivo (London et al., 2013). 
To circumvent these hindrances, many neuroscientists have turned to studying the retina, a 
comparatively accessible CNS structure found within the eye (Ames and Nesbett, 1981; Nowak, 
1987). 
The retina, a neural tissue that lines the posterior portion of the eye, is the first component 
of the visual system that encodes incident light from the environment into a neural signal that can 
be interpreted by the brain. As vertebrates develop embryonically, the retina and optic nerve 
form as an outgrowth of the brain’s diencephalon, and are therefore considered part of the CNS. 
                                                          
1
 Portions of this chapter were published as a co-authored review: Ho KW, Ward NJ, Calkins DJ. 
TRPV1: a stress response protein in the central nervous system (2012) Amer J Neurodegener Dis 
1:1-14. 
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Both the retina and optic nerve each partially house a unique type of neuron known as the retinal 
ganglion cell (RGC). Like other neurons of the CNS, the RGC neurons are specialized to serve a 
particular purpose, that is, to convey visual information from the retina to regions of the brain 
critical for vision. Although very specialized for the visual system, these neurons are known to 
exhibit similarities to other CNS neurons, as they respond similarly to injury and exhibit a 
diminished potential for axonal regeneration subsequent to injury (Crish and Calkins, 2011; 
London et al., 2013). 
Indeed, links between brain pathologies and degeneration of RGCs have been established 
in several diseases. In Alzheimer’s disease (AD), accumulations of β-amyloid (Aβ) and 
phosphorylated tau are associated with the degeneration of multiple brain regions (Wenk, 2003). 
Similarly, these accumulations exist in the retinas of both AD patients (Koronyo-Hamaoui et al., 
2011) and transgenic mouse models of the disease (Ning et al., 2008; Gasparini et al., 2011). In 
humans, AD patients exhibit reduced RGC numbers and degeneration of the optic nerve (Hinton 
et al., 1986; Sadun and Bassi, 1990). In multiple sclerosis (MS), a demyelinating disease, many 
patients are diagnosed with optic neuritis, in which RGC degeneration and demyelination is 
observed (Ghezzi et al., 1999). Therefore, it appears that RGCs may be adversely affected by AD 
and MS in much the same manner as other CNS neuronal populations. 
 Using this knowledge that RGCs can be affected by disease and injury in a similar 
fashion to other CNS neurons, it is reasonable to believe that studies of RGC degeneration could 
likewise inform research related to all CNS degenerative diseases. This document will present 
studies related to one such disease, glaucoma, which results in the degeneration of RGCs. Taking 
advantage of the accessibility of the retina, these studies examine how the cation channel 
transient receptor potential vanilloid-1 (TRPV1) influences RGC survival in response to 
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neuronal stressors in glaucoma. By understanding how TRPV1 influences survival in RGCs, we 
will be able to better determine how the channel may influence neurodegeneration throughout 
the CNS. 
 
Glaucoma pathogenesis 
 
Clinical presentation of glaucoma 
 Glaucoma is a family of optic neuropathies that causes progressive visual loss due to 
dysfunction and death of RGCs. It is the most common cause of irreversible blindness 
worldwide, and it is estimated that nearly 80 million people will be affected by this disease by 
the year 2020 (Quigley and Broman, 2006). Age and sensitivity to intraocular pressure (IOP) are 
the two main risk factors for developing glaucoma, and of these two, IOP is the only modifiable 
risk factor. 
 
Figure 1.1. Visual field defects in human glaucoma patients. Visual field maps were collected 
using standard automated perimetry on right eyes of patients. Each map is from the perspective 
of the patient, so the left side of each map is located nasally and the right side is located 
temporally. Darker areas represent reduction in sensitivity, and the natural blindspot can be 
observed in patients with normal visual field, as in A. Glaucoma typically affects peripheral 
vision first as in B and C. Late-stage patients who have very progressed visual field deficits 
retain vision only in their central visual field, as in D. 
 
Figure from Hollands et al. (2013), and used in accordance with Copyright Clearance Center’s 
RightsLink service. 
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 In the clinic, glaucoma is typically defined by a number of characteristics. Primary 
among these are deficits in the visual field and thinning of the retinal nerve fiber layer (RNFL). 
Visual field loss can be assessed by perimetry, in which the examiner maps the patient’s field of 
vision. Scotomas, or areas of visual field loss, are a hallmark of glaucoma (Figure 1.1). Although 
a variety of visual field defects are possible, the most common alterations to the visual field in 
glaucoma are arcuate scotoma (Levin, 2001). This scotoma commonly forms an arc that starts 
temporally near the region of the optic disc, curves around into the superior or inferior field, and 
ceases toward the nasal end of the horizontal axis (Figure 1.1B). Many patients do not notice the 
scotoma formation until it is well-progressed, as peripheral vision is affected much earlier than 
central vision (Figure 1.1D). The structural correlate of these visual field losses can be observed 
in the clinic by thinning of the RNFL, the retinal layer composed of RGC axons traversing 
toward the optic disc. Thinning of the RNFL is caused by loss of RGC axons, and can be 
associated with an increased “cupping” at the optic disc as observed in clinical ophthalmoscopic 
exams (Figure 1.2). 
 While outcome measures of glaucoma (e.g., visual field defects, RNFL thinning) are 
specific in nature, the etiology of this family of diseases is complex. To address this, cases of 
glaucoma that exhibit elevated IOP are typically grouped into one of two types: open angle and 
closed angle (Hollands et al., 2013). The “angle” referred to by each of these names is the 
iridocorneal angle formed by the iris and the cornea (Figure 1.3). The integrity of this angle is 
crucial for the proper drainage of aqueous humor, which both nourishes avascular eye tissue and 
maintains IOP. Aqueous humor is continuously produced in the posterior chamber of the eye, 
and it must flow through the pupil, into the anterior chamber of the eye, and finally exit at the 
angle via the trabecular meshwork (Figure 1.3). The proper balance of aqueous humor  
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Figure 1.2. Optic disc cupping in human glaucoma patients. The optic disc, where RGC axons 
leave the eye to form the optic nerve, is the anatomical location of the eye’s blind spot. A, A 
healthy optic nerve typically exhibits a slightly cupped shape (inner circle, central cup) where the 
RGC axons come together while leaving the retina. B, As glaucoma progresses, loss of RGC 
axons results in a thinning of the retinal nerve fiber layer that contributes to the shape of the 
central cup. When these axons are lost, the size of the central cup increases. When examining the 
eye, clinicians often speak of glaucoma patients exhibiting a high cup-to-disc ratio, meaning that 
the size of the central cup is large with respect to the size of the entire optic disc structure. 
 
Figure from Hollands et al. (2013) and used in accordance with Copyright Clearance Center’s 
RightsLink service. 
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production and drainage maintains IOP within the eye, thus any blockage or defects that exist in 
structures at the angle may disturb regulation of IOP. 
 
 
Figure 1.3. Production and outflow of aqueous humor in the eye. Aqueous humor is continually 
produced by the ciliary body to nourishes avascular eye tissue as well as to maintain intraocular 
pressure (IOP). This fluid enters the anterior chamber through the pupil and subsequently leaves 
the anterior segment of the eye through drainage structures at the iridocorneal angle (see inset, 
left). When the eye is healthy (left panel), production of aqueous humor and outflow of aqueous 
humor are in a proper balance that maintains IOP in what is generally considered to be a normal 
range (≤ 21 mmHg). In primary open angle glaucoma (right panel), outflow of aqueous humor 
through the trabecular meshwork is diminished or obstructed in some way. The resulting build-
up of aqueous humor in the anterior eye results in an increase in IOP because the correct balance 
of aqueous production and outflow has been disturbed. 
 
Figure from Hollands et al. (2013) and used in accordance with Copyright Clearance Center’s 
RightsLink service. 
 
 
 Closed angle glaucoma (CAG) arises from the iris pressing against the cornea, thereby 
closing the angle and preventing proper aqueous outflow (Nongpiur et al., 2011). Patients with 
CAG typically exhibit abnormally high IOP, which can create ocular pain (Salmon, 1999). 
Conversely, open angle glaucoma (OAG) is not painful and patients exhibit no angle closure. 
OAG involves the degradation and obstruction of the trabecular meshwork, leading to a decrease 
in outflow facility at the angle (Quigley, 1993). Decreased aqueous outflow, in turn, results in an 
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increase in IOP (Figure 1.3). Both CAG and OAG are associated with increases in IOP, thus 
measurement of IOP by tonometry is often a component of eye exams. Although ocular 
hypertension is associated with glaucoma, some patients exhibit disease progression despite 
never developing an elevated IOP, a condition deemed normotensive glaucoma (Heijl et al., 
2002; Iester et al., 2012). Although these patients exhibit what is considered a normal IOP in the 
clinic, this does not mean that these patients progress solely due to IOP-independent 
mechanisms. In support of this idea, it has been determined that patients with normotensive 
glaucoma often benefit from IOP-lowering regimens (Heijl et al., 2002). It is therefore important 
to understand that glaucoma is not necessarily a disease related exclusively to IOP elevations, 
but rather to IOP sensitivity (Crish and Calkins, 2011). 
 
RGCs and their susceptibility to glaucomatous neurodegeneration 
 All glaucomatous pathology ultimately converges upon the dysfunction and degeneration 
of RGCs. In humans, there are approximately 1.5 million RGCs, which possess the unique task 
of gathering information from other cells in the retina and conveying that information along their 
lengthy axons to distal brain regions (Campbell et al., 2013). To examine the implications of 
RGC death, it is critical to first understand the important role these neurons play within the 
context of the entire visual projection system. 
 Within the retina, visual information is first encoded when photons of light activate rod 
and cone photoreceptor cells in the outer retina (Figure 1.4). Photoreceptors release glutamate to 
activate bipolar cells, which in turn release glutamate to activate RGCs. Feed-forward signaling 
across the retina is most simply achieved at the two excitatory synapses between these three  
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Figure 1.4. Retinal circuitry and layers. Traveling in the direction of the arrow (bottom, left), 
light reaches the rod and cone photoreceptors (with cell bodies in the outer nuclear layer, ONL) 
and is transduced into a neural signal. Transmission of visual information proceeds from 
photoreceptors to bipolar cells (with cell bodies in the inner nuclear layer, INL), and then from 
bipolar cells to ganglion cells (with cell bodies in the ganglion cell layer, GCL). This information 
is passed from one cell to another at excitatory synapses found in the outer plexiform layer 
(OPL) and inner plexiform layer (INL). Activity at these synapses are modulated by horizontal 
cells (at the OPL) and amacrine cells (at the IPL). As the ganglion cells course through the nerve 
fiber layer (NFL) toward the optic disc, they interact directly with astrocytes. In addition to 
astrocytes, other glial cells, such as microglia and Müller glia influence proper function within 
the retina as well as the overall health of the neuronal cells. 
 
Figure from Calkins (2012) and used in accordance with Copyright Clearance Center’s 
RightsLink service.  
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classes of neurons. Feed-forward retinal signaling is regulated by two sets of interneurons: 
horizontal cells in the outer retina and amacrine cells in the inner retina. Horizontal cells are  
GABAergic and modulate activity at synapses between photoreceptors and bipolar cells, while 
amacrine cells are mostly GABAergic and glycinergic and modulate synaptic activity between 
bipolar cells and RGCs (Wassle and Boycott, 1991; Oesch et al., 2011). Health and activity of all 
retinal cell types are additionally influenced by three retinal glial cells: astrocytes, microglia, and 
Müller glia. 
 Visual information that has been processed through the feed-forward pathway is then 
carried away from the retina along RGC axons. These axons exit the retina at the optic disc, at 
which point they bundle together to form the optic nerve. RGC axons terminate at several targets 
in the brain, particularly the lateral geniculate nucleus (LGN) in the thalamus and the superior 
colliculus (SC) in the midbrain. In primates, RGCs project primarily to the LGN, while only 
~10% of RGCs project to the superior colliculus (Bunt et al., 1975; Perry et al., 1984; Liu et al., 
2011). In contrast, rodent RGCs project primarily to the superior colliculus, with only ~30% of 
RGCs projecting to the LGN (Dreher et al., 1985). Unlike in primates, where half of RGCs cross 
to contralateral structures and the other half project ipsilaterally, the large majority of rodent 
RGCs project to contralateral brain structures, with only 3-10% of RGCs projecting ipsilaterally 
(Drager and Olsen, 1980; Jeffery, 1984; Kondo et al., 1993; Liu et al., 2011). 
 In glaucoma, it is known that dysfunction and death of RGCs results in progressive 
blindness, but less is known about why RGCs are the cells primarily affected in glaucoma. It has 
long been posited that pressure contributes to biomechanical stress on RGC axons as they leave 
the retina at the optic nerve head, and that this may contribute to damage (Burgoyne et al., 2005); 
however, it is likely that components intrinsic to RGCs make them particularly susceptible to 
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degeneration as well. More recent hypotheses suggest that a confluence of factors may determine 
the primary degeneration of RGCs in glaucoma (Calkins, 2012). These factors may include: (1) 
the relative thinness of RGC axons, (2) the presence of an energetically-demanding 
unmyelinated portion of the RGC axon, (3) a diminishment of transport of mitochondria along 
axons, and (4) a pressure-related reduction in ATP along the optic nerve. 
 
Degenerative progression in glaucoma 
 Although the etiology of glaucoma is complex and not fully explained by current 
research, much more is known about the pathophysiological changes that occur in glaucoma due 
to disease modeling in animals. It is understood that during the course of glaucoma, RGCs 
exhibit signs of dysfunction preceding obvious structural degeneration and loss of neurons in the 
retina (Crish et al., 2010). It has also been determined that diminished visual function occurs 
prior to wide-scale loss of RGC somas in the retina (Harwerth et al., 2002). Developing 
knowledge of disease progression will therefore allow for targeted therapeutic interventions 
before dramatic vision loss occurs. 
 Thus far, deficits in anterograde axonal transport along the optic nerve are one of the 
earliest detectable signs of RGC dysfunction in animal models. Axonal transport is a method by 
which neurons are able to move cargo—organelles, lipids, synaptic vesicles, and proteins—from 
the cell body out toward synaptic terminals (anterograde transport) or from the terminals toward 
the cell body (retrograde transport). Cargo is transported along cytoskeletal tracks via motor 
proteins known as kinesin and dynein, which move in an anterograde and retrograde direction, 
respectively (Roy et al., 2005). Healthy axonal transport is critical to neurons because, among 
other functions, they depend on it to redistribute mitochondria to energetically demanding 
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regions of the neuron (Hollenbeck and Saxton, 2005) and to shuttle neurotrophic factors, which 
can influence cell survival (DiStefano et al., 1992). 
The temporal progression of axonal transport deficits has perhaps been characterized best 
in studies using the DBA/2 mouse. In the DBA/2 mouse, which exhibits progressive glaucoma as 
animals age, significant RGC soma death begins at approximately 18 months, though some 
studies suggest it may begin earlier (Reichstein et al., 2007; Buckingham et al., 2008). However, 
when evaluating deficits in anterograde axonal transport, the earliest deficits are observed in 3-
month-old DBA/2 mice (Crish et al., 2010). This indicates that one of the earliest known deficits 
exist far in advance of the final stage of RGC degeneration—caspase-dependent apoptotic cell 
death (Garcia-Valenzuela et al., 1995; Kerrigan et al., 1997). In fact, anterograde transport is 
almost completely lost by 11 to 12 months in DBA/2 mice, again prior to significant RGC death 
in the retina (Buckingham et al., 2008; Crish et al., 2010). Retrograde transport is affected later 
than anterograde transport, as studies in DBA/2 mice indicate deficits are first observed at 6-8 
months (Buckingham et al., 2008). 
 In addition to disruptions in axonal transport, degeneration of axons in the optic nerve 
occurs prior to RGC soma loss in the retina as well. Axon density within the optic nerve was 
reduced starting at 13 months in the DBA/2 mouse, and this reduction in density is accompanied 
by disrupted axon fascicles and enlarged astrocytic processes (Buckingham et al., 2008). In a 
meta-analysis of studies using RGC soma counts in the retina and RGC axon counts in the optic 
nerve, it was apparent that reduction of axons was 2-3 times greater than reductions in RGC 
soma counts, even across different cumulative exposures to IOP (Calkins, 2012). 
 Although RGC death in the retina stands as the final stage of glaucomatous progression, 
disease-relevant alterations are not simply confined to the RGC axon alone. In 12-month-old 
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DBA/2 mice with observed optic nerve pathology, certain RGCs exhibited a reduction in 
dendritic branching as well as abnormal dendritic arbors when compared to controls (Jakobs et 
al., 2005). Likewise, one study found less PSD-95 present at synaptic sites in the inner plexiform 
layer of the retina in 10.5-month-old DBA/2 mice, likely indicating of dendritic retraction or 
pruning (Stevens et al., 2007). This assertion was strengthened by the presence of a concomitant 
upregulation of C1q protein, which may help target dendrites for pruning by microglia (Stevens 
et al., 2007). It is not yet clear how early dendritic changes occur, but these results indicate that it 
may happen alongside the development of pathology in the optic nerve. 
 Although dendritic pruning and synaptic elimination may occur at intermediate stages of 
disease progression, it appears that RGC axon terminals persist at target sites in the brain. In the 
DBA/2 mouse, immunolabeled presynaptic terminals from RGC axons persist within the SC for 
up to 18-22 months (Crish et al., 2010). This matches well with data suggesting that retrograde 
axonal transport, which exhibits deficits later than anterograde transport, persists up to 18 
months in DBA/2 mice (Buckingham et al., 2008). This knowledge of structural persistence at 
distal brain sites is encouraging, especially when paired with the idea that therapeutics could 
focus on rescuing dysfunctional neurons before cellular structures degenerate.  
While the DBA/2 mouse model of glaucoma has been highly informative in establishing 
a progression of degeneration, this model is not without its limitations. The DBA/2 has two 
mutations that result in a pigmentary form of glaucoma. These mutations in the Gpnmb and 
Tyrp1 genes cause iris pigment dispersion and iris stromal atrophy, respectively (Anderson et al., 
2002). The dispersion and atrophy entail sloughing off of iris pigment and cell debris into the 
ocular drainage structures, which obstructs aqueous outflow and gradually elevates IOP. In these 
mice, IOP elevation and disease progression are variable—the majority of mice have elevated 
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IOP by 5 to 6 months of age, but some present with elevated pressure by 3 months, and still 
others never show any pressure elevation (Inman et al., 2006). In addition, the level of IOP 
elevation also varies in these mice, ranging anywhere from 2.5 to 8 mmHg depending on the age 
and sex of the mouse (Inman et al., 2006). Finally, variables such as colony of origin (DBA/2J 
versus DBA/2NCrl versus DBA/2NTac), diet, along with other environmental factors all 
influence the natural history of disease in DBA/2 mice (McKinnon et al., 2009). 
In consideration of the limitations of the DBA/2, we and other investigators have 
developed methods to induce ocular hypertension (elevated IOP) acutely. These models include 
laser photocoagulation of episcleral veins (WoldeMussie et al., 2001), episcleral vein occlusion 
(Garcia-Valenzuela et al., 1995), sclerosis of episcleral veins by injection of hypertonic saline 
(Morrison et al., 1997), and microbead occlusion of aqueous humor drainage (Sappington et al., 
2010). In these models, IOP is typically elevated in one eye, leaving the other to serve as an 
internal control. We use the microbead model as it provides a reliable and robust (25 to 35%) 
increase in IOP, it is reproducible across cohorts, and IOP elevation can be sustained for multiple 
weeks in mice. The microbead model is also effective in inducing optic nerve pathology, as axon 
counts are reduced by approximately 20% following 4 weeks of elevated IOP. This model does 
not exhibit issues such as ocular ischemia and neovascularization, both of which can confound 
interpretation of data (Goldblum and Mittag, 2002; Pang and Clark, 2007). Ultimately, what 
makes this model so useful is that it produces IOP elevation that is more in line with pressure 
elevation seen in human disease (~38% elevation for moderate cases), whereas other models use 
50-100% elevations that may not be a proper physiological representation of elevations seen in 
untreated human glaucoma (Sommer et al., 1991; Sappington et al., 2010). 
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Neurodegeneration in glaucoma 
 
 Within the CNS, neurodegenerative diseases such as Alzheimer’s disease (AD), 
amyotrophic lateral sclerosis (ALS), Parkinson’s disease (PD), and Huntington’s disease (HD) 
exhibit diverse etiologies and a wide range of clinical presentations. Nevertheless, the underlying 
neurodegenerative cellular mechanisms often exhibit remarkable similarities (Crish and Calkins, 
2011; London et al., 2013). In this section, we will first cover features that are common to most 
neurodegenerative diseases, such as dysregulation of Ca
2+
, excitotoxicity, mitochondrial 
dysfunction, and disruption of axonal transport. Following that, we will examine how glaucoma 
shares common characteristics and cellular mechanisms with other neurodegenerative diseases. 
 
Ca
2+
 homeostasis is dysregulated in neurodegeneration 
 Ca
2+
 is an important intracellular messenger that regulates a variety of important neuronal 
functions like neurotransmitter release, neuronal responses to the binding of neurotransmitter, 
potentiation and depression of synaptic activity, and gene transcription (Berridge, 1998; Berridge 
et al., 2000; Gleichmann and Mattson, 2011). While essential to many cellular processes, this 
cation functions under tight regulation by the cell; situations in which Ca
2+
 exceeds its typical 
spatial and temporal limits can result in irreversible damage. Across a number of 
neurodegenerative diseases, dysregulation of Ca
2+
 homeostasis is a common feature that 
underlies pathogenesis (Marambaud et al., 2009). 
 Two parts of the machinery that regulates the levels of intracellular Ca
2+
 are membranous 
ionotropic glutamate receptors known as NMDA and Ca
2+
-permeable AMPA receptors (Figure 
1.5). When these receptors are activated in an excessive manner, Ca
2+
 entry into the cell becomes  
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Figure 1.5. Dysregulation of Ca
2+
 in neurodegenerative disease. Many pathways converge upon 
Ca
2+
 overload as a damaging agent in neurodegenerative disease. Disease-relevant stressors such 
as excitotoxicity and decreased expression of Ca
2+
 buffering proteins contribute to an overload of 
Ca
2+
 within neurons. This excessive Ca
2+
 overloads the buffering potential of mitochondria and 
also activates damaging Ca
2+
-activated proteases known as calpains. As mitochondria 
dysfunction, they are prone to release cytochrome c, inducing mitochondrially-mediated 
apoptosis of the affected neuron. 
 
Figure from Marambaud et al. (2009) and used in accordance with the Creative Commons 
Attribution License 4.0 (http://www.creativecommons.org/licenses/by/4.0/). 
 
 
neurotoxic, a phenomenon known as excitotoxicity (Arundine and Tymianski, 2003). The 
propensity for certain neurons to experience excitotoxicity can be influenced by the type of 
receptors those cells express. For instance, not all AMPA receptors can flux Ca
2+
, and this is 
dictated by the GluR2 subunit; if a GluR2 subunit is present in the AMPA receptor, it cannot flux 
Ca
2+
. This is particularly relevant in ALS, as AMPA receptors in the affected spinal motoneurons 
appear to all lack GluR2 subunits, which may contribute to Ca
2+
-mediated excitotoxicity 
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(Carriedo et al., 1996; Williams et al., 1997; Takuma et al., 1999). Additionally, protein 
aggregates that form in some neurodegenerative disease may influence the activity of NMDA 
receptors, pushing them toward a more excitotoxic activity profile (Sun et al., 2001; Shankar et 
al., 2007). For example, in AD aggregates of Aβ may directly associate with NMDA receptor 
subunits, causing an increase in channel activity and a resulting increase in Ca
2+
 flux into the cell 
(Shankar et al., 2007). 
Multiple stressors can cause dysregulation of Ca
2+
 in neurodegenerative diseases. In AD, 
altered cleavage of amyloid precursor protein generates Aβ, which is toxic to neurons (Mattson, 
2004). Formation of Aβ oligomers is associated with the production of reactive oxygen species 
(ROS), which results in membrane-associated oxidative stress (MAOS). MAOS involves lipid 
peroxidation, which disrupts the function of both Na
+
/K
+
- and Ca
2+
-ATPases as well as 
transporters of glutamate and glucose (Mattson, 1998). This results in depolarization of the 
membrane and influx of Ca
2+
 through NMDA receptors and voltage-dependent Ca
2+
 channels 
(Mattson, 2007). Aside from AD, there is evidence for MAOS occurring in degenerating neurons 
in PD (Yoritaka et al., 1996) and ALS (Smith et al., 1998) as well. 
Due to the dynamic nature of Ca
2+
 entry and activity within cells, it is important that 
neurons are able to buffer any excess intracellular Ca
2+
. Specific proteins called Ca
2+
 buffering 
proteins are critical for this buffering process. Degenerative pathology has been associated with 
changes related to various Ca
2+
 buffering proteins, including calbindin-D28K, calmodulin, and 
parvalbumin (Figure 1.5). A common feature of motoneurons affected earliest in ALS is that 
they do not express calbindin-D28K or parvalbumin, which may render them susceptible to 
aberrant Ca
2+
 (Alexianu et al., 1994). Additionally, calbindin-D28K and calmodulin protein and 
mRNA levels are known to be reduced in several cortical regions in AD, showing that the ability 
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to buffer Ca
2+
 declines in areas susceptible to degeneration (McLachlan et al., 1987; Ichimiya et 
al., 1988). 
In addition to being buffered by proteins, intracellular Ca
2+
 concentrations can be reduced 
via uptake of Ca
2+
 by mitochondria. However, when levels of Ca
2+
 within mitochondria become 
too high, mitochondrial dysfunction occurs (Figure 1.5), which may involve opening of the 
mitochondrial permeability transition (MPT) pore (Hunter and Haworth, 1979; Brustovetsky et 
al., 2002). Opening of the MPT pore allows Ca
2+
 to leave mitochondria again, which causes 
intracellular Ca
2+
 to elevate once again. Prolonged opening of MPT can result in other 
deleterious effects: disruption of the electron transport chain, reduced ATP production, increased 
production of reactive oxygen species, and release of cytochrome c from mitochondria (Buki et 
al., 2000; Luetjens et al., 2000; Stavrovskaya and Kristal, 2005). Cytochrome c release can cause 
activation of caspase-dependent cellular apoptosis, thus opening of the MPT can have dire 
consequences for neurons (Green and Reed, 1998). Studies in HD determined that mutant 
huntingtin protein could directly induce MPT pore opening due to a lowered tolerance of the 
Ca
2+
 load within mitochondria (Panov et al., 2002; Panov et al., 2003; Choo et al., 2004). This 
type of interaction also seems to occur in AD, in which Aβ accumulation in mitochondria may 
also aid in mediating Ca
2+
-induced MPT opening (Reddy and Beal, 2008). 
 As intracellular Ca
2+
 increases to non-homeostatic concentrations within neurons, 
degenerative cascades are activated. Ca
2+
 can directly activate proteases known as calpains, 
which cleave cytoskeletal proteins, components of synapses, receptors, and enzymes involved in 
metabolism (Chan and Mattson, 1999; Lu et al., 2000; Vosler et al., 2008). Calpain activation 
due to dysregulated Ca
2+
 can therefore promote mechanisms that cause disruptive changes to 
neurons. Calpain-mediated cleavage of Bax is a feature of PD, and this cleavage promotes 
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release of cytochrome c from mitochondria, which pushes the neurons toward death (Choi et al., 
2001). Calpains can also activate abnormal phosphorylation activity of several varieties of 
kinases, which in turn phosphorylate neurofilaments and tau protein, ultimately resulting in 
dysfunctional axon transport (Shea et al., 2004; Goni-Oliver et al., 2007; Morfini et al., 2009b).  
 
Axonal transport disruption in neurodegenerative diseases 
 Disruption of neuronal function in neurodegenerative disease often includes development 
of deficits in axonal transport. The axon is therefore a challenging feature for neurons, as 
important cellular components necessary for axonal function must be transported from their 
location of synthesis in the cell body (Morfini et al., 2009b). In neurodegenerative diseases, there 
is evidence for abnormal phosphorylation of motor proteins, which leads to dysfunction of 
axonal transport. In HD, polyglutamine expansion of the huntintin protein (polyQ-Htt) is 
associated with neurodegeneration in the striatum and cerebral cortex (Sieradzan and Mann, 
2001). PolyQ-Htt was determined to causes deficits in axonal transport by activating a neuron-
specific kinase called JNK3, which phosphorylates kinesin protein (Morfini et al., 2009a). 
Similarly, kinase activity in AD is altered (Pigino et al., 2001; Wang et al., 2007), and one of 
these kinases—casein kinase 2 is activated and disrupts axonal transport via increased 
phosphorylation of kinesin-1 light chain (Pigino et al., 2009). This deregulated phosphorylation 
results in the uncoupling of kinesin-1 from its cargo, and thus disrupting transport along the 
axon. 
 Phosphorylation of motor proteins is not the only way that axonal transport can be 
disrupted in neurodegeneration. Excessive phosphorylation of neurofilaments can also be 
detrimental to axonal transport. Neurofilaments are cytoskeletal elements that are longitudinally 
19 
 
oriented in the axon. Neurofilaments were first named according to their molecular mass—light 
(NF-L), medium (NF-M), and heavy (NF-H)—however, a fourth subunit named α-internexin has 
since been discovered (Julien and Mushynski, 1998; Yuan et al., 2006). Of these four subunits, 
both NF-M and NF-H have long C-terminal regions commonly known as their side arms, which 
can be extensively phosphorylated (Julien and Mushynski, 1998). Increasing side arm 
phosphorylation decreases the affinity of NFs for kinesin (Yabe et al., 1999), and increases their 
affinity for dynein (Motil et al., 2006); therefore, these NFs are not anterogradely transported 
along the axon, where they are needed. Instead, increased affinity for dynein causes them to be 
transported retrogradely and accumulate at the cell soma. Additionally, the phosphorylated 
neurofilaments (pNFs) tend to bundle together, which considerably slows down anterograde 
transport by kinesin (Shea and Chan, 2008). Elevated or mislocated pNF and hyper-pNF have 
been reported in many neurodegenerative diseases, including ALS (Sobue et al., 1990), MS 
(Petzold et al., 2008), AD (Stokin et al., 2005), and glaucoma (Soto et al., 2008). 
 
Degenerative cellular mechanisms in glaucoma 
 Although direct evidence for excitotoxicity in models of glaucoma is relatively scarce 
(Carter-Dawson et al., 2002; Levkovitch-Verbin et al., 2002; Casson, 2006), NMDA antagonists 
MK-801 (Chaudhary et al., 1998) and memantine (Hare et al., 2004a; Hare et al., 2004b) both 
exhibited a neuroprotective effect in models of glaucoma. Of these two drugs, memantine was 
tested for use with human patients in a set of clinical trials, which were deemed unsuccessful 
(Osborne, 2009). It has been hypothesized that glaucoma may be mediated in part by insufficient 
blood supply, potentially due to increased IOP or other risk factors that could reduce ocular 
blood flow (Flammer et al., 2002). Based on this hypothesis, RGC death may in part be due to 
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excitotoxic damage downstream of ischemia-reperfusion injury (Osborne et al., 1999; Flammer 
et al., 2002). One study used a rat model of retinal ischemia/refusion induced by non-
physiologically high IOP (120 mmHg for 45 minutes) to demonstrate that intraocular 
administration of Coenzyme Q10 (CoQ10) afforded neuroprotection to RGCs by preventing 
mitochondrial permeability transition pore formation (Nucci et al., 2007a). While these 
mechanisms may be protective, it is difficult to assess whether or not these mechanisms are 
relevant to human glaucoma as it presents in the clinic, especially given the use of non-
physiological IOP elevations. Presently, it is poorly understood how much of a role excitotoxic 
Ca
2+
 entry plays a role in glaucomatous degeneration. 
 Ca
2+
 binding proteins may be relevant in some initial responses to elevated pressure, as 
RGC-associated expression of Ca
2+
 buffering proteins parvalbumin and calbindin-D28K were 
transiently upregulated following pressure elevation in rats (Wang et al., 2005). The authors 
indicated that this upregulation was prior to loss of RGCs in the retina—it is possible that RGCs 
may use these buffering proteins to address the presence of aberrant Ca
2+
. Excessive intracellular 
Ca
2+
 can activate calpains, and this activation has been observed in a rat model of glaucoma 
(Huang et al., 2010). In other neurodegenerative diseases (Vosler et al., 2008), calpains activate 
cyclin dependent kinase 5 (Lee et al., 2000), glycogen synthase kinase 3(Goni-Oliver et al., 
2007), and c-Jun N-terminal kinases/JNK (Tan et al., 2006; Morfini et al., 2009b). Overactive 
phosphorylation of neurofilaments and the microtubule associated protein tau by kinases results 
in axonal transport deficits (Shea et al., 2004; Morfini et al., 2009b), which are a hallmark of 
glaucoma (Anderson and Hendrickson, 1974; Crish et al., 2010; Howell et al., 2012). In DBA/2 
mice, somatic and somatodendritic accumulations of phosphorylated neurofilaments were 
associated with RGCs exhibiting failure of axonal transport (Soto et al., 2008). The kinases 
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associated with this excessive phosphorylation activity can affect motor protein activity as well: 
glycogen synthase kinase 3 phosphorylates kinesin, resulting in its dissociation from cargo, and 
JNK phosphorylates kinesin, inhibiting its ability to bind microtubules (Morfini et al., 2009b). 
Early changes in kinase activity in glaucoma may therefore influence onset and progression of 
axonal dysfunction (Crish and Calkins, 2011). 
 Dysregulated Ca
2+
 is also known to influence the development of oxidative stress through 
mechanisms such as increased neuronal metabolic rate and activation of ROS-producing 
enzymes (Abramov et al., 2007; Zundorf et al., 2009; Crish and Calkins, 2011). DBA/2 mice 
exhibit lipid peroxidation and upregulated oxidative stress-related proteins during pathogenesis, 
so a group of studies was focused on addressing the relative contribution of oxidative stress to 
glaucoma pathogenesis (Inman et al., 2013). In these studies, dietary supplementation with 
antioxidant α-lipoic acid reduced measures of oxidative stress, increased expression of 
antioxidant proteins, and increased protection of RGCs (Inman et al., 2013). This protection 
afforded by α-lipoic acid supplementation therefore indicates that oxidative stress contributes to 
the degenerative outcome of RGCs during the course of glaucoma. 
 
Protective responses of the retina and RGCs 
 Although neurodegenerative cellular signaling drives neurons toward cell death, there is 
evidence for intrinsic protective mechanisms that slow this progression. In a study of both 
experimental glaucoma and optic nerve transection, upregulation of both proapoptotic and 
prosurvival genes occurred simultaneously in the retina (Levkovitch-Verbin et al., 2006). In this 
study, proapoptotic gene Gadd45a was significantly upregulated 1 week after IOP elevation and 
remained upregulated for 2 months, whereas upregulation of prosurvival gene Iap-1 returned to 
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baseline prior to Gadd45a. RGCs exposed to elevated pressure in vitro exhibited upregulation of 
apoptotic genes, but these cells likewise showed a protective response through upregulation of 
the prosurvival Bcl-2 gene (Sappington et al., 2006). These studies indicate that both RGCs and 
the retina as a whole have protective responses to counter the stresses of the degenerative milieu 
of glaucoma. 
 As in other neurodegenerative conditions, oxidative stress is a detrimental feature of 
glaucoma (Lin and Beal, 2006; Tezel, 2006). The retina combats oxidative stress associated with 
IOP elevation by reducing the formation of damaging reactive oxygen species (ROS). In the 
DBA/2 mouse, ceruloplasmin protein is upregulated in order to reduce iron-mediated 
mechanisms of ROS formation (Steele et al., 2006). This increase was observed in 5-month-old 
animals, suggesting that this protein is involved in an early response to glaucomatous stressors. 
In addition to ceruloplasmin, increases in other antioxidant proteins are elevated in the retina or 
aqueous humor in monkeys and humans with glaucoma (Farkas et al., 2004; Ferreira et al., 2004; 
Ghanem et al., 2010). 
 Many of these studies examining protective responses examine the retina as a whole 
tissue; however, this makes it difficult to determine if RGCs have intrinsic mechanisms for 
responding to glaucomatous stress and damage. Driving synaptic activity, even in injured or 
degenerating neurons, has been demonstrated to help neurons survive (Corredor and Goldberg, 
2009). For example, after optic nerve axotomy in rats, stimulating retinal neurons using a trans-
corneal electrode increased RGC survival in vivo (Morimoto et al., 2005). It is important to 
consider, then, if RGCs make any attempt to bolster their synaptic connections in an effort to 
survive degenerative stressors. Evidence from manganese-enhanced MRI of DBA/2 mice 
indicated that very little difference was seen in cationic activity in the DBA inner retina when 
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comparing between ages associated with axonopathy and those considered pre-axonopathy 
(Calkins et al., 2008). This may support the idea that despite degenerative progression, RGCs 
make an effort to maintain their synaptic activity in the inner retina as part of an effort to survive. 
 
Ca
2+
-mediated plasticity and a role for TRPV1 in neuronal survival 
 
Role of Ca
2+
 in homeostatic synaptic plasticity 
 In cases of injury and disease, CNS neurons undergo plasticity that involves rewiring of 
neural circuitry (Moore et al., 2000; Kaas et al., 2008). Reductions in synaptic connectivity as 
well as dendritic retraction and abnormalities are common features of neurodegenerative diseases 
and injury (Posmantur et al., 1996; Lin and Koleske, 2010; Furutani and Kibayashi, 2012). 
However, it has been hypothesized that neurons may actually take an active role in maintaining 
synaptic activity following injury in order to recover and preserve function (Lee, 2012). In 
models of neuronal insult and injury (Liu et al., 2006; Spaethling et al., 2008), Ca
2+
-permeable 
AMPA receptors were upregulated in neurons and their synaptic sites. Increased localization of 
Ca
2+
-permeable AMPA receptors to postsynaptic specializations of neurons is often involved in 
potentiating activity at synapses (Malenka and Bear, 2004). It is not yet understood whether this 
increase in receptors contributes further to Ca
2+
-related pathology or instead helps bolster 
neuronal activity and connectivity (Liu et al., 2006; Lee, 2012). It is known that many neurons 
exhibit homeostatic synaptic plasticity, meaning they are able to monitor their activity and in 
turn modify the strength of a synapse by trafficking glutamatergic receptors to or from that 
synapse (Ibata et al., 2008; Turrigiano, 2008; Lee, 2012). Altogether, these homeostatic 
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mechanisms would be useful when healthy neuronal function is compromised, especially given 
that maintaining activity is critical for neuronal survival (Corredor and Goldberg, 2009). 
 In terms of understanding neuronal responses to injury, cultures of mechanically lesioned  
leech nerve cord are used to better understand regenerative neurite outgrowth following CNS 
injury. One group demonstrated that endocannabinoids, a group of neuromodulatory lipids, were 
involved in neurite outgrowth following damage; however, they could not identify leech 
orthologs for the cannabinoid receptors CB1 and CB2 (Meriaux et al., 2011). Endocannabinoids, 
however, are also known to activate the TRPV1 receptor (Ross, 2003). TRPV1 is a polymodal 
cation channel with a high preference for fluxing Ca
2+
, and it can be activated by heat, pH, and 
vanilloid compounds like capsaicin (Ho et al., 2012). Meriaux et al. (2011) confirmed that 
leeches possessed orthologs to the TRPV family of proteins, and then tested how neurite 
outgrowth was modulated by two agonists (arvanil and capsaicin) and one antagonist 
(capsazepine) of mammalian TRPV1. Both agonists accelerated neurite outgrowth and the 
antagonist halted all outgrowth. Intriguingly, this study showed that, subsequent to CNS injury in 
the leech, a TRPV1-like protein modulates neurite outgrowth. 
 
Potential for TRPV1 to influence RGC survival in vivo 
 Immunolabeling for TRPV1 in primary cultures of RGCs reveals that this protein is 
expressed throughout the RGC, including all neurites (Sappington et al., 2009). In the DBA/2 
mouse, TRPV1 exhibits an interesting expression pattern: at older ages and higher IOP, TRPV1 
expression is especially localized to the inner plexiform layer, the layer of the retina into which 
RGC dendrites project (Sappington et al., 2009). This is interesting because Ca
2+
-permeable 
AMPA receptors exhibit localization to synaptic sites following neuronal insult and injury (Liu 
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et al., 2006). TRPV1 is also permeable to Ca
2+
, so if it localizes to RGC dendrites, it could exert 
beneficial or deterimental effects depending on its function. Previous studies in vitro indicated 
that Ca
2+
 influx into cultured RGCs exposed to pressure is partly mediated by TRPV1 
(Sappington et al., 2009). In vitro, this is detrimental and causes apoptosis, especially given the 
acute nature of the stressor used. In vivo, this Ca
2+
 entry may be important, especially if TRPV1 
is upregulated in RGC dendrites, where it could help modulate homeostatic synaptic interactions 
in response to stress (Lee, 2012). If this actually occurs, it would not be the first example of 
TRPV1 affording RGCs protection from damage, as has previously been demonstrated in models 
of NMDA-induced neuronal injury and ischemia-reperfusion injury (Nucci et al., 2007b; 
Sakamoto et al., 2014). 
 
TRPV1 modulates CNS function 
 
The TRP channel family 
The transient receptor potential (TRP) family is a diverse group of channels that regulates 
cation entry and contributes to a vast variety of physiological conditions. In mammals, there are 
28 TRPs, divided into 6 subfamilies based on homology: canonical (TRPC1-7), vanilloid 
(TRPV1-6), melastatin (TRPM1-8), ankyrin (TRPA1), polycystin (TRPP1-3) and mucolipin 
(TRPML1-3). All six subfamilies share a common structure of six transmembrane domains with 
a hydrophobic pore located between the fifth and sixth domains. Situated in the plasma 
membrane, TRP channels serve as polymodal integrators due to their activation by a variety of 
stimuli including temperature, osmolality, mechanical force, chemoattractants and ischemia. 
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One subfamily of the TRP channels is the vanilloid family, named for their 
responsiveness to various ligands that possess vanillyl moieties. Within the TRPV family, 
TRPV1 is the best studied particularly due to its role in nociception. Although first identified as 
the receptor for capsaicin, TRPV1 can also be activated endogenously by voltage, noxious heat 
(>42°C), pH and lipoxygenase products. Endocannabinoids, including anandamide and N-
arachidonoyl dopamine, can activate both TRPV1 and cannabinoid receptors, indicating the 
importance of cross-talk mechanisms. TRPV1 nonselectively gates cations; however, channel 
activation results in a 10-fold higher preference for Ca
2+
 (Chung et al., 2008). Functional TRPV1 
preferentially forms a homotetramer but can also oligermerize with other TRP family subunits 
including TRPV3 and TRPA1 (Smith et al., 2002; Moiseenkova-Bell et al., 2008; Staruschenko 
et al., 2010). 
 
The structure of TRPV1 
Structural analysis of TRPV1 indicates a compact transmembrane region and a large 
basket-like intracellular domain (Moiseenkova-Bell et al., 2008). The intracellular N-terminal 
tail contains numerous phosphorylation sites and ankyrin repeats that serve as binding sites for 
calmodulin and ATP (Lishko et al., 2007). The intracellular C-terminal tail contains a TRP 
domain as well as binding sites for both calmodulin and PIP2, an endogenous TRPV1 inhibitor 
(Numazaki et al., 2003; Garcia-Sanz et al., 2004; Ufret-Vincenty et al., 2011). Agonist activation 
is also mediated intracellularly, as lipophilic capsaicin readily crosses the membrane to bind 
several sites on TRPV1 (Figure 1.6). The cation selectivity filter for TRPV1 is believed to lie in 
the pore domain formed by transmembrane regions 5 and 6. This selectivity is dynamic, not 
static, and can vary depending on stimulus duration or agonist concentration. Activation can alter  
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Figure 1.6. TRPV1 is a member of the transient receptor potential family. TRPV1 consists of six 
transmembrane domains with a pore region between the fifth and sixth domain, and long 
intracellular N- and C- terminal tails. Within the N-terminal tail, six ankyrin repeat domains 
allow binding of calmodulin and ATP to modulate TRPV1 activation. The C-terminus contains a 
TRP domain as well as binding sites for PIP2 and calmodulin. Throughout TRPV1 are multiple 
phosphorylation sites for PKA, PKC and CaMKII, in addition to putative sites for capsaicin and 
proton binding. 
 
Figure from Ho et al. (2012) and used in accordance with the Creative Commons Attribution 
Noncommercial License.  
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the Ca
2+
 permeability and pore diameter of TRPV1 to allow influx of larger cations (Chung et 
al., 2008). The method of channel stimulation can also have a significant effect on Ca
2+
 
permeability—activation by protons produces a smaller Ca2+ current than activation by capsaicin 
(Samways et al., 2008). 
 
 
Figure 1.7. Interaction with other signaling pathways can traffic TRPV1 to the plasma 
membrane. TrkA stimulation by NGF can cause src-mediated phosphorylation of TRPV1 to 
traffic TRPV1 from the endoplasmic reticulum to the plasma membrane. Translocation of 
TRPV1 to the membrane can also be increased through PKA- and PKC-mediated 
phosphorylation. Dephosphorylation by SHP-1, however, can inhibit translocation. 
 
Figure from Ho et al. (2012) and used in accordance with the Creative Commons Attribution 
Noncommercial License. 
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Regulation of TRPV1 
In addition to membrane expression, TRPV1 is also found in the endoplasmic reticulum 
where it mobilizes Ca
2+
 from intracellular stores (Liu et al., 2003; Marshall et al., 2003). 
Activation of signaling pathways can translocate TRPV1 from intracellular compartments to the 
membrane usually via phosphorylation. For example, PKC activation can lead to membrane 
insertion of TRPV1 via SNARE-mediated exocytosis (Morenilla-Palao et al., 2004). 
Furthermore, nerve growth factor activation of the tyrosine kinase src can phosphorylate TRPV1 
to increase membrane localization (Figure 1.7). 
Phosphorylation is also important in modulating the channel, allowing for rapid responses 
to external stimuli or environmental changes. Generally, phosphorylation sensitizes while 
dephosphorylation desensitizes the channel. PKC phosphorylation reverses desensitization of 
TRPV1 from prolonged capsaicin treatment and increases the sensitivity of TRPV1 to agonists 
(Mandadi et al., 2006; Varga et al., 2006). PKA can also reduce desensitization by direct 
phosphorylation of TRPV1 (Bhave et al., 2002). In addition, PKC or PKA activation through 
stimulation of multiple receptors including the protease-activated receptor PAR2, bradykinin B1 
and B2, purinergic P2 receptors, chemokine receptor CCL3, and endothelin receptors have all 
been shown to increase sensitivity of the channel (Figure 1.8). On the other hand, 
dephosphorylation by calcineurin/PP2B and increases in intracellular Ca
2+
 can desensitize the 
channel (Koplas et al., 1997; Mohapatra and Nau, 2005). 
 
TRPV1 in the CNS 
Although it is expressed throughout the CNS, TRPV1 is most robust in the sensory 
neurons of the dorsal root ganglion (Sanchez et al., 2001). Using a combination of knockout  
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Figure 1.8. TRPV1 is a polymodal cation channel. TRPV1 can be activated by a variety of 
noxious stimuli such as heat, pH and pressure, and its interaction with other receptors including 
G protein-coupled receptors (GPCRs) contributes to its polymodal nature. GPCR activation can 
directly lead to recruitment of PKC and PKA, through phospholipase C and adenylyl cyclase 
respectively, to phosphorylate TRPV1 and sensitize the channel. Elevations in intracellular Ca
2+
 
from TRPV1 and GPCR stimulation can activate calcineurin and CaMKII via calmodulin to 
further modulate TRPV1 activity. 
 
Figure from Ho et al. (2012) and used in accordance with the Creative Commons Attribution 
Noncommercial License. 
 
mice, radioligand binding and immunocytochemistry, TRPV1 expression within the CNS has 
been documented. These studies localize TRPV1 mainly to the hippocampus and cortex with 
additional expression in hypothalamus, olfactory nuclei, dentate gyrus, locus coeruleus, superior 
colliculus and spinal cord (Roberts et al., 2004; Toth et al., 2005). These observations of 
widespread TRPV1 expression, however, are contested by a TRPV1 reporter mouse that 
indicates limited expression in the CNS outside of nociceptors in the sensory ganglia. CNS 
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expression was restricted to the posterior caudal hypothalamus, the rostral midbrain, the 
periaqueductal grey and the hippocampus (Cavanaugh et al., 2011). Although there is 
discrepancy regarding the exact distribution of TRPV1, it can be appreciated that CNS 
expression of TRPV1 indicates a broader function of the channel beyond sensory transmission. 
Subcellularly, TRPV1 expression has been found in cell bodies and synapses, 
predominantly on the post-synaptic dendritic spines of neurons and also in synaptic vesicles 
(Toth et al., 2005; Goswami et al., 2010; Puente et al., 2011; Puente et al., 2014). TRPV1 is also 
highly expressed in the cell bodies and neurites of both sensory neurons and neurons 
differentiated by induction with retinoic acid (Puntambekar et al., 2005; El Andaloussi-Lilja et 
al., 2009). Retinal ganglion cells also exhibit TRPV1 expression in somas and in discrete pockets 
in axons (Sappington et al., 2009). In addition to neurons, TRPV1 protein has also been found in 
glia including astrocytes and microglia (Doly et al., 2004; Sappington and Calkins, 2008). 
 
TRPV1 in neuronal function 
As a cation channel that preferentially fluxes Ca2+, TRPV1 is also involved in neurite 
outgrowth and growth cone dynamics. Growth cones are incredibly dynamic and undergo rapid 
directional changes in response to a chemical gradient. Localized elevations in Ca
2+
 at the 
growth cone can induce extension and turning by activating CaMKII for attraction and 
calcineurin for repulsion (Zheng, 2000; Wen et al., 2004). Neurite outgrowth is also believed to 
be Ca
2+
 dependent. By interacting with microtubule kinase MARK2, CaMKI is able to induce 
neurite outgrowth under conditions of increased intracellular Ca
2+
 (Uboha et al., 2007). In 
retinoic acid-induced differentiation of neuroblastoma cells into neurons, TRPV1 is upregulated 
in both cell bodies and developing neurites (El Andaloussi-Lilja et al., 2009). Activation of 
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TRPV1 can also induce the formation of varicosities along neurites and retraction of growth 
cones through microtubule disassembly in a dorsal root ganglia cell line (Goswami et al., 2007).  
In addition to growth cones and neurites, TRPV1 also localizes to synapses, and 
emerging studies indicate the channel can modulate synaptic transmission. In a DRG cell line, 
TRPV1 colocalizes with synaptic proteins at filopodia tips, where activation results in vesicle 
fusion. This activity suggests that TRPV1 modulates neurotransmitter release (Goswami et al., 
2010). For example, capsaicin can activate a subset of neurons in the solitary tract to induce an 
inward current and an increase in spontaneous activity to facilitate glutamate release (Doyle et 
al., 2002; Peters et al., 2010). Furthermore, in DRG and spinal cord co-cultures as well as slices 
from substantia nigra and hypothalamus, capsaicin increases presynaptic Ca
2+
 to enhance 
presynaptic activity and glutamate release (Sasamura et al., 1998; Marinelli et al., 2003; 
Medvedeva et al., 2008). In addition to glutamate release, TRPV1 has also been implicated in 
dopamine release at the nucleus accumbens and in enhancing the firing of dopaminergic neurons 
(Marinelli et al., 2005). In the peripheral nervous system, capsaicin-induced Ca
2+
 increases lead 
to the release of neuropeptides substance P and calcitonin-gene related peptide (Gazzieri et al., 
2007; Huang et al., 2008). 
 
TRPV1 in synaptic transmission and plasticity 
By altering synaptic Ca
2+
 levels and neurotransmitter release, TRPV1 can modulate 
synaptic transmission. In spinal cord slices from rats injected with Freund’s complete adjuvant, 
the TRPV1 antagonist, SB-366791 decreases the frequency but not amplitude of spontaneous 
and miniature excitatory post-synaptic currents (EPSCs) (Lappin et al., 2006). In striatal medium 
spiny neurons and sensory neurons, TRPV1 enhances the frequency of glutamatergic EPSCs that 
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were potentiated by PKC-mediated decrease in desensitization (Sikand and Premkumar, 2007; 
Musella et al., 2009). TRPV1-mediated increases in EPSC frequencies have also been observed 
in the substantia gelatinosa, periaqueductal gray, medial preoptic nucleus, substantia nigra and 
locus coeruleus (Marinelli et al., 2003; Karlsson et al., 2005; Xing and Li, 2007; Jiang et al., 
2009). 
By modulating synaptic transmission, TRPV1 can influence synaptic plasticity and 
survival. In hippocampal neurons, TRPV1 activation by capsaicin or 12-(S)-HPETE is necessary 
to cause long-term depression (LTD) by high frequency stimulation. This effect was notably 
absent in TRPV1-null mice (Gibson et al., 2008). As a result of this finding, the authors propose 
a model in which glutamate induces post-synaptic release of 12-(S)-HPETE into the synaptic 
cleft to activate presynaptic TRPV1 channels. Activated TRPV1 subsequently decreases pre-
synaptic glutamate release through a Ca
2+
-dependent pathway (Figure 1.9). Another study found 
that in the dentate gyrus and in the medium spiny neurons of the nucleus accumbens, post-
synaptic activation of TRPV1 by anandamide leads to LTD through Ca
2+
-mediated endocytosis 
of AMPA receptors (Chavez et al., 2010; Grueter et al., 2010). In the developing superior 
colliculus, TRPV1 antagonist iodoresiniferatoxin (I-RTX) blocks the induction of tetanus-
induced LTD, while an agonist, resiniferatoxin (RTX), reduces the amplitude of field excitatory 
postsynaptic potentials (Maione et al., 2009). In TRPV1-null mice, there was a reduction in long-
term potentiation (LTP) compared to wild type mice in the CA1 region of the hippocampus 
(Marsch et al., 2007). These previous studies indicate that TRPV1 facilitates LTD; however, 
another study found that capsaicin and RTX amplified LTP and suppressed LTD in the CA1 
region of the hippocampus (Li et al., 2008). 
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Figure 1.9. TRPV1 contributes to synaptic plasticity. As a calcium cation channel, TRPV1 has 
been implicated in synaptic plasticity, especially in facilitating long term depression. (A) 
Activation of mGluR by glutamate triggers the synthesis and release of 12-(S) HPETE into the 
extracellular milieu. 12-(S)HPETE activates pre-synaptic TRPV1, and through a Ca
2+
-mediated 
pathway, glutamate release is blocked. (B) mGluR activation can also lead to production and 
release of anandamide. Anandamide binds postsynaptic TRPV1 to cause endocytosis of AMPA 
receptors, or to pre-synaptic cannabinoid receptors to inhibit glutamate release. 
 
Figure from Ho et al. (2012) and used in accordance with the Creative Commons Attribution 
Noncommercial License. 
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TRPV1 in neurodegeneration 
Associated with increases in intracellular Ca
2+
, overactivation of TRPV1 can be toxic to 
cells. Capsaicin leads to elevated levels of intracellular Ca
2+
 and subsequent mitochondrial 
damage and apoptosis in both cultured cortical microglia and mesencephalic neuronal cultures 
(Kim et al., 2005; Kim et al., 2006). Capsaicin can also induce apoptosis of cultured retinal 
ganglion cells in a dose-dependent manner (Sappington et al., 2009). Likewise, intranigral 
injections of capsaicin lead to death of dopaminergic neurons through Ca
2+
-mediated 
mitochondrial damage. This damage can be reduced by coinjections of capsazepine (Kim et al., 
2005). Moreover, capsaicin triggers apoptosis in cortical neurons through ERK phosphorylation, 
activation of caspases and production of reactive oxygen species (Shirakawa et al., 2008). 
TRPV1 has also been found in gliomas, where its activation by capsaicin leads to cell death 
through Ca
2+
-induced mitochondrial damage and p38 activation (Amantini et al., 2007). The 
association between TRPV1 and cell death is further supported by the ability of I-RTX to block 
pressure-induced apoptosis of cultured retinal ganglion cells (Sappington et al., 2009). 
Because TRPV1 can initiate Ca
2+
-dependent apoptosis of neuronal and glial cell types, 
TRPV1 has been implicated in neurodegeneration. Intriguingly, TRPV1 appears to modulate 
aspects of neurodegeneration, and can even influence neuroprotective mechanisms. In a gerbil 
model of global transient ischemia, capsaicin and the CB1 receptor antagonist rimonabant can 
both improve locomotor activity, memory and the number of neurons in the CA1 hippocampus. 
This effect is diminished with capsazepine pre-treatment, suggesting that TPRV1 is 
neuroprotective during ischemia (Pegorini et al., 2005; Pegorini et al., 2006). Capsaicin has also 
exhibited a neuroprotective function in ouabain-mediated excitotoxicity (Veldhuis et al., 2003). 
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This protection may be mediated by rapid agonist-induced desensitization of TRPV1, as TRPV1 
antagonism by capsazepine was also neuroprotective and could reduce brain damage. 
TRPV1 has also been implicated in Huntington’s disease (HD), a genetic 
neurodegenerative disorder characterized by cell death in the basal ganglia. HD arises from the 
expansion of the polyglutamine tract in the huntingtin protein, causing gain-of-function. The 
symptoms of HD include motor defects as well as cognitive and psychiatric problems. In a 3-
nitropropionic acid-induced model of Huntington’s disease, the endocannabinoid ligand AM404 
is able to reduce hyperkinesia (Lastres-Becker et al., 2003). This phenomenon can be reversed by 
capsazepine, but not by the CB1 antagonist SR141716A, suggesting that TRPV1 activation can 
reduce locomotion. Capsaicin itself is antihyperkinetic and can restore dopamine and GABA 
transmission in the basal ganglia (Lastres-Becker et al., 2003). Furthermore, intraperitoneal 
injections of capsaicin into rats reduce ambulation and stereotypic behavior and increase 
inactivity time during open field testing (Di Marzo et al., 2001). These studies indicate that drugs 
targeting TRPV1 might be beneficial to patients diagnosed with HD. The ability of TRPV1 to 
modulate behavior related to degenerative disease as well as its ability to influence neuronal 
survival, indicate that TRPV1 is a particularly interesting channel to study in the context of 
neurodegenerative diseases. 
 
TRPV1 in glaucomatous neurodegeneration 
 TRPV1 activity is known to modulate aspects of neurodegeneration, and can influence 
survival of many different subsets of neurons. Based on previous in vitro and in vivo studies of 
the effects of TRPV1 activity on RGC survival, it is likely that TRPV1 influences 
neurodegenerative progression in glaucoma. Studies using in vitro cultures of RGCs indicated 
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that TRPV1 antagonism reduced pressure-induced RGC death (Sappington et al., 2009). This 
study suggests that TRPV1 activation may be deleterious during disease progression. However, 
in an ischemia-reperfusion injury model using extreme intraocular pressure elevation, RGC 
survival was increased, in part, by TRPV1 activation. In this in vivo model, both CB1 and 
TRPV1 protein levels were upregulated. Treatment with a stable anandamide analogue reduced 
RGC loss, an effect that was diminished with CB1 and TRPV1 antagonists (Nucci et al., 2007b). 
This suggests that endocannabinoid binding to CB1 or TRPV1 is neuroprotective, and that 
TRPV1 activity may be needed for survival mechanisms. Both of these studies indicate the 
importance of TRPV1 activity in modulation of disease progression; therefore, we made it our 
focus to understand how TRPV1 modulates RGC degenerative processes in an in vivo model of 
glaucoma. 
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Specific Aims of Dissertation 
 
The objective of this project is to examine how the cation channel TRPV1 (transient 
receptor potential vanilloid-1) modulates degenerative processes in RGCs during glaucoma. Our 
central hypothesis is that TRPV1 functions as a stress response protein that counteracts IOP-
related RGC dysfunction by enhancing excitatory activity at neuronal synapses. This hypothesis 
draws on the knowledge that retention of synapses requires maintenance of synaptic activity. 
Having previously implicated TRPV1 as a modulator of RGC survival in vitro (Sappington et al., 
2009), we are now prepared to address the function of this channel in a model of glaucomatous 
degeneration that results in reproducible and sustained elevation of IOP, the microbead occlusion 
model (Sappington et al., 2010). This modeling will allow us to directly assess TRPV1 function 
within the context of degenerative influences. To test our central hypothesis, we have developed 
these specific aims: 
 
Aim 1. Determine influence of TRPV1 on RGC degenerative outcomes. Our working 
hypothesis is that TRPV1 helps RGCs survive exposure to IOP-related stress. We will therefore 
examine whether TRPV1 knockout exacerbates RGC degenerative outcomes with microbead-
induced IOP elevations. We will (1) assess RGC dysfunction by examining axonal transport to 
the superior colliculus, and (2) quantify any changes in axon survival in the optic nerve. Within 
the retina, we will (3) quantify RGC soma survival and look for markers of dysfunction, such as 
accumulation of phosphorylated neurofilaments. 
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Aim 2. Determine compartmental nature of TRPV1 response in RGCs. Based on results in 
DBA/2 mice, our working hypothesis is that TRPV1 responds to elevated IOP by translocating to 
RGC dendrites. We will use microbead-induced IOP elevation to (1) determine changes in Trpv1 
mRNA over time using whole retina. Within the retina we will (2) determine if TRPV1 levels 
change in dendritic, somatic, and axonal RGC compartments, and we will (3) look for increased 
localization of TRPV1 near synaptic structures. 
 
Aim 3. Establish relevance of TRPV1 in survival of RGC dendrites. Our working hypothesis 
is that TRPV1 helps boost activity at RGC dendrites to counter their degenerative retraction. We 
will compare RGCs from C57 and Trpv1-/- mice to see if TRPV1 affects dendritic morphology 
in response to microbead-induced IOP elevations. 
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CHAPTER 2 
 
ABSENCE OF TRPV1 ACCELERATES STRESS-INDUCED AXONOPATHY 
IN THE OPTIC PROJECTION
2
 
 
Introduction 
Onset and progression of neurodegeneration in disease and injury involves integration of 
both protective and destructive intra- and extracellular signals (Schwartz and Yoles, 2000; Qu et 
al., 2010). Determining how relevant stressors mediate production of these signals is critical to 
understand disease progression and identify molecular targets for therapeutic intervention. The 
transient receptor potential (TRP) family of cation-selective ion channels mediates a variety of 
neuronal responses to both physiologic and pathogenic stimuli (Lin and Corey, 2005; Ho et al., 
2012; Vennekens et al., 2012). The diversity of TRP channels arises in part from the broad 
spectrum of ligand-based, membrane-bound and biophysical mechanisms through which they are 
activated. The capsaicin-sensitive vanilloid-1 channel TRPV1 exemplifies this diversity, 
contributing to tactile sensitivity, diabetic sensory neuropathy, pressure-induced pain, injury 
monitoring and visceral distension (Mutai and Heller, 2003; Hwang et al., 2004; Rong et al., 
2004; Scotland et al., 2004; Jones et al., 2005; Ma et al., 2005; Liedtke, 2006; Plant et al., 2006; 
Daly et al., 2007; Pingle et al., 2007). Like other TRP channels, TRPV1 activation is associated 
with a robust Ca
2+
 conductance that supports many Ca
2+
-dependent intracellular cascades linked 
to both normal signaling and stress-related processes (Agopyan et al., 2004; Aarts and 
Tymianski, 2005; Reilly et al., 2005; Kim et al., 2006; Miller, 2006). 
                                                          
2
 Portions of this chapter were published as Ward NJ, Ho KW, Lambert WS, Weitlauf C, Calkins 
DJ (2014) Absence of transient receptor potential vanilloid-1 accelerates stress-induced 
axonopathy in the optic projection. J Neurosci 34:3161-3170. 
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In the optic projection, retinal ganglion cells (RGCs) and their axons express TRPV1 and 
other TRP channels, which upon activation increase intracellular Ca
2+
 and modulate survival of 
RGCs challenged by different disease-relevant stressors such as ischemic insult and pressure 
(Nucci et al., 2007b; Maione et al., 2009; Sappington et al., 2009; Wang et al., 2010; Ryskamp et 
al., 2011; Leonelli et al., 2013). TRPV1 also contributes to retinal glial cell signaling and may 
modulate RGC survival indirectly through inflammatory cytokine pathways (Sappington and 
Calkins, 2008). These results all have bearing on RGC survival in glaucoma, the most common 
optic neuropathy and leading cause of irreversible blindness worldwide (Quigley and Broman, 
2006). Glaucoma involves sensitivity to intraocular pressure (IOP), a potent stressor that induces 
early RGC axonal dysfunction with subsequent optic nerve degeneration and later loss of RGC 
bodies in the retina (Calkins, 2012; Howell et al., 2012). We have presented evidence that 
TRPV1 in RGCs contributes to transducing stress typically associated with glaucoma 
(Sappington et al., 2009). In this chapter, I tested how genetic knock-out of Trpv1 (-/-) influences 
progression of RGC degeneration with exposure to elevated IOP in an inducible model. 
 Trpv1-/- mice are viable, but demonstrate phenotypic alterations when compared to their 
C57BL/6 counterparts. These mice exhibit reductions in nociception, thermal hypersensitivity 
after inflammation, and responses to vanilloid stimulation (Caterina et al., 2000; Davis et al., 
2000). Trpv1-/- mice additionally demonstrate alterations in neuronal function in the central 
nervous system (Ho et al., 2012). Several studies have also used Trpv1-/- mice to demonstrate 
the importance of TRPV1 in synaptic plasticity, particularly in long-term potentiation (Marsch et 
al., 2007; Li et al., 2008) and long-term depression (Gibson et al., 2008; Maione et al., 2009; 
Chavez et al., 2010; Grueter et al., 2010). 
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The alterations observed in Trpv1-/- mice indicate that TRPV1 influences neuronal 
physiology and synaptic function. By examining Trpv1-/- mice in our inducible model of 
glaucoma, we are able to examine how this channel functions in response to degenerative 
stressors in vivo. This model elevates IOP by using microbeads to occlude aqueous humor 
outflow from the anterior segment of the eye. To examine the effect Trpv1-/- has on degenerative 
progression, we compared Trpv1-/- and C57BL/6 mice based on their responses to microbead 
injections. We examined outcome measures that have been previously used with this model, 
including quantification of deficits in axonal transport, decreased density of axons in the optic 
nerve, and loss of RGC somas in the retina (Crish et al., 2010; Sappington et al., 2010; Dapper et 
al., 2013). Accelerated pathology in Trpv1-/- microbead animals compared to C57BL/6 controls 
indicates that TRPV1 contributes to an intrinsic stress response present in RGCs. 
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Materials and Methods 
Animals, tissue harvesting, and tissue preparation 
All rodent experiments were conducted following protocols approved by the Vanderbilt 
University Medical Center Institutional Animal Care and Use Committee. C57BL/6 (C57) mice 
were obtained from Charles River (Wilmington, MA) and B6.129X1-Trpv1
tm1Jul
/J (Trpv1-/-) 
mice were obtained from Jackson Laboratories (Bar Harbor, ME). All mice were maintained in a 
12-h light/dark cycle with standard rodent chow available ad libitum as previously described 
(Crish et al., 2010). 
 
Trpv1-/- mouse 
 For all Trpv1-/- mouse experiments, B6.129X1-Trpv1
tm1Jul
/J mice were obtained from 
Jackson Laboratories (Bar Harbor, ME). This knockout is a germ-line mutation that was created 
by deletion of an exon encoding part of the fifth and all of the sixth transmembrane domains of 
the TRPV1 channel, including the pore-loop region between the two. This Trpv1-/- strain is 
maintained at Jackson and was created by Julius and colleagues using methods described 
elsewhere (Caterina et al., 2000). Briefly, mouse-specific Trpv1 primers were used to produce a 
129/SVJ mouse genomic DNA clone of part of the Trpv1 gene. A 10-kb subfragment of this 
clone was produced by HindIII digestion and was used as a targeting vector for transfection of 
JM1 embryonic stem (ES) cells (Qiu et al., 1995). 
ES cells were electroporated by Julius and colleagues with the targeting vector DNA, and 
screened via ganciclovir/geneticin double selection for homologous recombination at the Trpv1 
locus (Caterina et al., 2000). One of these clones was used for injection of C57 mouse 
blastocysts, which were subsequently implanted into pseudopregnant Black/Swiss female mice. 
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Male offspring with chimeric coats were mated with C57 females, and the resulting Trpv1+/- 
males were backcrossed to C57 females for multiple (≥4) generations. Trpv1+/- offspring were 
then intercrossed to generate Trpv1-/- mice on a C57 genetic background. 
Southern blot analysis of genomic DNA from Trpv1+/+, Trpv1+/-, Trpv1-/- mice 
confirmed proper targeting and disruption of the Trpv1 gene (Caterina et al., 2000). Northern 
blot analysis of Trpv1 mRNA expression in dorsal root ganglia (DRG) indicated the presence of 
Trpv1 transcript in Trpv1+/+ and Trpv1+/-, but not Trpv1-/- mice (Caterina et al., 2000). 
Additionally, no protein gene product is detected in DRG (JAX® Mice Database; 
http://jaxmice.jax.org/strain/003770.html). Loss of TRPV1 immunoreactivity in Trpv1-/- mice 
was verified in the supraoptic and paraventricular nuclei (Sharif Naeini et al., 2006) using a C-
terminal antibody to TRPV1 (Neuromics), and in the lumbar spinal cord using antisera (from 
David Julius, UCSF) raised against the C-terminus of TRPV1 (Tominaga et al., 1998; Caterina et 
al., 2000). Specificity of the mouse-specific C-terminal TRPV1 antibody from Neuromics was 
demonstrated in both Western blots and immunolabeled tissue from mouse retina (Sappington et 
al., 2009). Western blots demonstrated full-length TRPV1 at 90 to 113 kDa depending on 
glycosylation state, and 198 kDa for TRPV1 dimers (Sappington et al., 2009). 
 
Trpv1-/- and C57 mouse genotyping 
Trpv1-/- mice were created on a C57BL/6 (C57) background, so C57 mice are used as 
controls (Caterina et al., 2000; Ciura and Bourque, 2006; Treesukosol et al., 2007). All mice 
used in Trpv1-/- experiments were genotyped to verify Trpv1 gene knockout. 3mm x 3mm ear 
clippings were collected from all mice used in Trpv1-/- experiments, and tissue was placed in 
microcentrifuge tubes on dry ice. DNA was extracted using the DNeasy Blood and Tissue Kit 
45 
 
(Qiagen, MD) following the Bench Protocol: Animal Tissues (Spin Column) protocol. 
Concentration of DNA was determined using a NanoDrop 8000 (Thermo Scientific, Wilmington, 
DE) and DNA was stored at 4ºC prior to running PCR reactions. 
Each PCR reaction was 25 µl in volume and contained the following: 2.5 µl 10X PCR 
Buffer (Invitrogen), 0.75 µl 50 mM MgCl2 (Invitrogen), 0.5 µl 10 mM dNTP mix (Promega, 
Madison, WI), 0.5 µl of each primer (10 µM working stocks; Integrated DNA Technologies), 
0.1µl Platinum Taq polymerase (Invitrogen), 40 ng of extracted template DNA, and the correct 
amount of DNase/RNAse free water to increase the total reaction volume up to 25 µl. I 
determined the volume of DNA to add by dividing 40 ng by the sample’s concentration as 
determined by the NanoDrop. For detection of Trpv1 gene truncation in Trpv1-/- mice, two 
forward primers were used to produce wild-type (Jackson Laboratory, oIMR1561; 5' CCT GCT 
CAA CAT GCT CAT TG 3') and knockout (Jackson Laboratory, oIMR0297; 5' CAC GAG ACT 
AGT GAG ACG TG 3') gene products, both of which used a shared reverse primer (Jackson 
Laboratory, oIMR1562; 5' TCC TCA TGC ACT TCA GGA AA 3'). With this primer 
combination, wild-type animals yield a product size of 984 bp and Trpv1-/- animals yield a 
product size of 600 bp. Positive control detection of Gapdh gene products used forward (5’ TTG 
GCA TTG TGG AAG GGC TC 3’) and reverse (5’ TGC TGT TGA AGT CGC AGG AGA C 
3’) primers to detect a 363 bp product. All tubes were lightly centrifuged prior to running PCR 
reactions. 
PCR reactions were carried out using a Mastercycler gradient thermocycler (Eppendorf 
AG, Hamburg, Germany) using the following cycling steps: 
Step 1: Denaturing: 94ºC for 3 minutes 
Step 2: Denaturing: 94ºC for 30 seconds 
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Step 3: Annealing: 65ºC for 1 minute 
Step 4: Extension: 72ºC for 1 minute 
Step 5: Repeat steps 2-4 40 times 
Step 6: Extension: 72ºC for 2 minutes 
Step 7: Finish, holding reactions at 4ºC 
 PCR products from these cycling steps were used as template DNA for a second round of 
PCR using the same steps. A second round of PCR was necessary because the first round did not 
yield enough product to detect bands on an agarose gel. These reactions all used 2.7 µl of first 
round PCR product, and the reactions were set up the same, only adjusting the amount of 
DNase/RNAse free water added to produce a final volume of 25 µl per reaction. 
Second round PCR products and a 100 bp DNA ladder (New England BioLabs) were 
separately mixed with 6X loading dye (Fermentas) and separated at 100 V for 45 minutes on a 
1.5% agarose gel (1.5 g agarose in 100 ml 1X TAE) stained with ethidium bromide. Gels were 
digitally imaged on a Gel Doc XR+ (Bio-Rad, Hercules, CA) gel reader to confirm successful 
PCR reactions (Gapdh positive control) and to distinguish C57 and Trpv1-/- mice (984 bp and 
600 bp reaction products, respectively). 
 
Induction of ocular hypertension by microbead occlusion 
Intraocular pressure (IOP) was acutely elevated in 4-month-old C57 and Trpv1-/- mice by 
microbead occlusion of aqueous flow as described previously (Sappington et al., 2010). Prior to 
injections, mice were anesthetized with isoflurane (Minrad Inc., Bethlehem, PA) and efficacy of 
anesthesia was evaluated by gentle pinching of the tail and paw. The eye was washed with a 
sterile saline solution and received application of 1% tropicamide ophthalmic drops (2-3 drops) 
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to dilate the iris. Local anesthetic drops containing 0.5% proparacaine were also applied to the 
eye. This solution is used to maintain eye moisture and provide pre- and post-operative 
analgesia. Drops of antibiotic tobramycin ophthalmic solution (0.3%, Akorn) were also applied 
prior to the injection to counter infection. 
For microbead injection into the anterior chamber, a standard microinjection setup 
(World Precision Instruments) consisting of a microsyringe pump and micromanipulator was 
used. This setup included a borosilicate microneedle (pulled to a final diameter of 100µm) 
attached to a syringe filled with mineral oil. The needle tip was sterilized with 100% EtOH 
before drawing the solution to be injected into the microneedle. We unilaterally injected 1.0µl of 
PBS containing inert polystyrene microbeads (15µm diameter; 1 x 10
6
 microbeads/ml solution; 
Life Technologies, Carlsbad, CA) into the anterior chamber of the eye (Figure 2.1). We injected 
the contralateral eye with an equivalent volume of PBS containing no microbeads for an internal 
control. Following the procedure, additional numbing drops containing 0.5% proparacaine were 
applied to both eyes. 
IOP was measured in anesthetized (2.5% isoflurane) mice at least twice weekly using 
TonoPen XL (Medtronic Solan, Jacksonville, FL) rebound tonometry as previously described 
(Inman et al., 2006; Sappington et al., 2010). An IOP measurement was determined as the mean 
of at least 20 readings. To avoid corneal irritation, hydrating eye drops were administered to each 
eye following IOP measurements. IOPs were measured for 2 days prior to microbead procedures 
to calculate an average baseline value (day 0) for each eye of every animal. 
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Figure 2.1. Elevation of intraocular pressure by microbead occlusion of aqueous outflow. 
Occluding aqueous outflow in rodents is an in vivo method for modeling pressure-related 
glaucomatous stressors. Polystyrene microbeads are injected into the anterior chamber of the eye 
using a glass micropipette (top left). Beads accumulate and settle at the irido-corneal angle (top 
right; arrow), impeding outflow of aqueous humor through drainage structures. Decreased 
outflow of aqueous humor results in an increased intraocular pressure in microbead-injected eyes 
when compared to eyes injected with an equivalent volume of saline (bottom left). Elevated 
pressure causes pathology seen as early as 3 weeks, such as RGC axon loss (bottom right).  
 
Figure modified from Sappington et al. (2010), and used in accordance with fair use standards as 
specified by the publisher. 
 
Anterograde tracing of retinocollicular and retinogeniculate tracts 
To establish an example of healthy anterograde transport from the retina to LGN and SC, 
we conducted tract tracing in a C57 mouse not previously injected with microbeads. Forty-eight 
hours prior to sacrifice, the mouse was anesthetized with 2.5% isoflurane before injections of 
tracer. Using a Hamilton syringe and 33 gauge, 0.375-inch needle, we injected 0.5 mg cholera 
toxin subunit B (CTB; Molecular Probes, CA) in 1 µl of sterile water into each eye (Figure 2.2). 
To highlight eye-specific projection systems, the injected CTB was conjugated either to Alexa 
Fluor-488 (green; left eye) or Alexa Fluor-594 (red; right eye). In addition to this naïve mouse, 
we also conducted tracing in microbead-injected animals. These mice were anesthetized and  
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Figure 2.2. Anterograde tracing of the mouse retinogeniculate and retinocollicular tracts. A, 
Schematic representing eye-specific ipsilateral and contralateral RGC axon projections from the 
retina to the dorsal and ventral lateral geniculate nuclei (d/vLGN) and superior colliculi (SC). 
Fluorescently-labeled CTB tracers (red and green fluorophores) injected into mouse eyes are 
anterogradely transported to both thalamic (d/vLGN) and midbrain (SC) structures. At the optic 
chiasm, RGC axons either cross the midline or project to structures on the same side as their eye 
of origin. Rodents exhibit extensive decussation at the optic chiasm, with only a small percent of 
axons projecting to ipsilateral brain structures. Contralateral projection systems are represented 
by thick lines while ipsilateral projection systems are represented by thin lines. B, dLGN and 
vLGN from the same C57 brain show dominant contralateral with smaller ipsilateral projections. 
C, Coronal section shows both SC near the rostral pole following bilateral intravitreal injection 
of cholera toxin B (CTB) into left (green CTB) and right (red CTB) eyes of C57 mouse. 
Fluorescent signal for dominant contralateral projection is over-exposed purposely to reveal 
sparser ipsilateral projection (arrows) for each eye. Medial (M), rostral (R), and dorsal (D) 
orientations indicated. Scale = 200 µm in all images.  
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injected with CTB in the same manner as the naïve animal, with the only difference being that 
these animals were given bilateral injections of Alexa Fluor-488. 
Animals were transcardially perfused with phosphate buffered saline (PBS) followed by 
4% paraformaldehyde (PFA) in PBS and tissue was harvested. Brains were cryoprotected 
overnight in 30% sucrose/PBS and 50 µm coronal sections were taken through the midbrain and 
thalamus on a freezing sliding microtome. Alternating sections of brain containing superior 
colliculus and lateral geniculate nucleus were photographed using a Nikon Ti Eclipse microscope 
(Nikon Instruments Inc., Melville, NY) and intensity of CTB label in collicular sections was 
quantified using ImagePro (Media Cybernetics, Bethesda, MD) as previously described (Crish et 
al., 2010; Lambert et al., 2011). Fluorescent signal was normalized to background and intensity 
calculations from alternating sections were combined to reconstruct CTB signal intensity across 
a retinotopic map of the colliculus (Figure 2.3). We determined percentage of intact transport for 
each map, defined as percent of map area with intensity ≥70% maximum CTB signal. 
 
Preparation of optic nerves 
 Following transcardial perfusion with 4% PFA, optic nerves were removed from C57 and 
Trpv1-/- mice. A 3 mm section of optic nerve proximal to the globe was isolated, post-fixed for 1 
hour in 4% PFA, and prepared for embedding and semi-thin cross-sectioning. Optic nerves were 
placed in 12-well culture plates containing 0.1 M cacodylate buffer (CB) in a fume hood. Using a 
transfer pipette, nerves were moved from CB to 2% osmium for 45 minutes of incubation on ice. 
Nerves were then moved from 2% osmium to a well of fresh CB, and then immediately into 
another well of fresh CB. Nerves were then moved to a new culture plate of CB to remove the 
nerves from the fume hood. All containers and transfer pipettes that came in contact with  
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Figure 2.3. Creating a retinotopic map of fluorescent CTB transported to the SC. Serial sections 
of SC (left) with fluorescent CTB (green) transported along RGC axons projecting from the 
retina. Serial sections are oriented with the midline at top and organized in a rostral to caudal 
fashion. Average pixel intensity is measured across each row of pixels (horizontal dotted lines) 
and is represented colorimetrically (bracketed boxes; “warm” colors represent intact transport 
while “cool” colors represent transport deficits). Column of pixels generated for each section are 
lined up rostral to caudal to reconstruct a retinotopic heat map of transport across the entire SC. 
 
osmium were kept in a fume hood and disposed of properly. The nerves were washed 3 times for 
5 minutes each in CB at room temperature. 
 Nerves were dehydrated using a series of EtOH solutions of increasing percentage. 
Nerves were incubated with shaking for 30 minutes in each solution: 50%, 70%, 95%, 100% 
EtOH. Nerves were moved to a second batch of 100% EtOH to incubate for 15 minutes with 
shaking. Nerves were moved to a glass scintillation vial containing a 1:1 mixture of propylene 
oxide/EtOH. This vial was sealed and nerves were incubated for 30 minutes while shaking. 
Using a transfer pipetted fitted with a 20 µl-200 µl pipette tip, the 1:1 mixture of propylene 
oxide/EtOH was carefully removed and replaced with 100% propylene oxide. Nerves were 
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incubated in this solution for 1 hour with shaking. This solution was removed and replaced with 
a 1:1 mixture of propylene oxide/epon. Nerves were incubated in this solution overnight at 4ºC 
with shaking. This solution was removed and replaced with fresh 1:1 propylene oxide/epon. 
Nerves were incubated for at least 4 hours at room temperature with shaking. Nerves were 
removed from glass vials and transferred to a new culture plate containing 100% epon. These 
nerves were incubated overnight at room temperature in a vacuum containing Drierite dessicant. 
All propylene oxide solutions were discarded properly and all vials that came in contact with the 
solutions were stored in the fume hood until all solution was evaporated. 
 Nerves were placed in new 100% solutions of epon to incubate for 6 hours at room 
temperature in a vacuum. Nerves then were moved to new 100% epon to incubate overnight at 
room temperature in a vacuum. This 6-hour and overnight incubation was repeated once more, 
with the last incubation occurring in a flat mold in a vacuum. This flat mold was then placed 
within a 60ºC oven for 3 days in a tip box containing Drierite. Molds were trimmed with a razor 
blade such that the nerve was located in the center of a double pyramid shape of dried epon. 
Using an ultramicrotome with a diamond knife, 1-2 µm cross-sections of optic nerve were cut 
and collected on a slide using distilled water. Sections were dried onto the slide in a 60ºC oven 
until all water was evaporated, and were then left to cool to room temperature. 
 Slides were immersed for 28 minutes in 1% paraphenylenediamine (PPD) in a 1:1 
mixture of methanol and 2-propanol. Slides were then washed in twice in fresh mixtures of 1:1 
methanol/2-propanol with no PPD for 1 to 2 minutes each followed by a 1-minute wash in 100% 
EtOH. Sections were air dried before slides were placed in a humidified box with 1% Toluidine 
Blue placed drop-wise onto the slide until the sections were completely covered. The box was 
placed in a 60ºC oven for 20 minutes. Slides were rinsed with ddH2O and allowed to air dry. 
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Slides were cover slipped using Permount mounting media and allowed to dry overnight prior to 
imaging. 
 
Quantification of RGC axons 
 Photomicrographs of C57 and Trpv1-/- optic nerve cross-sections were acquired and 
assembled as a montage on a Nikon Ti Eclipse microscope (Nikon Instruments Inc., Melville, 
NY) using 100x oil-immersion and differential interference contrast optics. Images were 
contrast- and edge-enhanced using custom routines programmed for Image Pro (Media 
Cybernetics, Bethesda, MD). These routines screen out glia and identify myelin sheaths in order 
to detect and count RGC axons in the optic nerve (Figure 2.4). Using random sampling, these 
routines calculate average axon density for an optic nerve section. This density can be multiplied 
by nerve area to estimate the total number of axons in the nerve. Manual counts of a subset of 
these nerves were conducted to create a correction factor to adjust for undercounting by the 
routines. 
 
Immunohistochemistry in retinal wholemount tissue 
 Retinal wholemount tissue was retrieved by dissecting perfused C57 and Trpv1-/- mouse 
eyes under a dissecting scope. Prior to dissection, the superior pole of the eye was identified 
using vasculature surrounding the optic nerve as a landmark. Using microdissection scissors, the 
eye was cut in a circular fashion above the ora serrata, and #5 forceps were used to separate the 
retina from the ora serrata. The retina was removed from the optic disc with a cut using 
microdissection scissors. To flatten the retina in preparation for imaging, four relief cuts were  
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Figure 2.4. Quantification of axons in optic nerve sections. Sections of optic nerve are stained 
with p-phenylenediamine and imaged as a montage at 100X (left). Axons with intact myelin 
sheaths are identified and outlined by a computer program (middle) and counted (red; right). 
 
made to create a cross shape in which each of the arms represented a retinal pole (i.e., superior, 
nasal, inferior, temporal; Lambert et al., 2011). A small incision was placed in the superior arm 
to distinguish it and additionally aid in identification of the other poles. To improve antibody 
penetration and imaging of the tissue, vitreous was manually removed using forceps. 
 Whole retinal tissue was immersed in increasing sucrose/PBS solutions ranging from 
10% to 30%. Tissue was moved to higher concentrations of sucrose solution when tissue sank to 
the bottom of the solution. Once in 30% sucrose, retinas were incubated overnight at 4ºC. 
Following overnight incubation, the retinas were placed on glass microscope slides. These slides 
were placed on dry ice to allow the tissue to freeze through completely. The retinas were freeze-
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thawed in this manner a total of three times. Retinas were washed three times in PBS for 5 
minutes each. Tissue was blocked in a solution of 5% normal donkey serum plus 0.1% Triton-X 
100 diluted in PBS. Retinas were incubated in blocking solution overnight at 4ºC.  
 Retinas were immunolabeled for phosphorylated neurofilaments used to identify RGCs 
and their axons. Tissue was placed in a primary antibody solution of SMI31 antibody (1:1000; 
Sternberger Monoclonal Incorporated, Baltimore, MD) against phosphorylated neurofilaments 
diluted in 3% normal donkey serum plus 0.1% Triton-X 100 in PBS. Retinas were incubated in 
primary antibody solution for 4 days at 4ºC on a shaker. Retinas were washed 3 times in PBS for 
10 minutes each at room temperature. Tissue was then placed in a solution of donkey anti-mouse 
488 secondary antibody (1:200, Jackson), 1% normal donkey serum, and 0.1% Triton-X 100 
diluted in PBS. Tubes containing retinas were covered with foil and incubated overnight at 4ºC 
with shaking. Retinas were then washed three times in PBS for 10 minutes each. Each retina was 
mounted RGC side up on a slide under a dissecting microscope using aqueous mounting media 
(Fluoro-mount). Slides were coverslipped and allowed to dry overnight in the dark at room 
temperature and were then sealed along the coverslip edges using Cytoseal. 
 
RGC soma quantification 
 To identify RGCs, whole-mounted retinas were stained for phosphorylated 
neurofilaments (SMI31 antibody; Sternberger Monoclonal Incorporated, Baltimore, MD), which 
identify RGC cell bodies and axons. To assess RGC survival in the retina, 0.101 mm
2
 were 
captured of C57 and Trpv1-/- retinas on an Olympus FV-1000 inverted confocal microscope. For 
each retina, images were captured along the midline of each retinal quadrant at 0.75, 1.5, 2.25, 
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and 3.0 mm from the optic disc following previously published methods (Lambert et al., 2011). 
SMI31-positive RGCs were counted for each image to calculate RGC density as cells per mm
2
. 
 
Mapping of CTB transport onto retinal quadrant and eccentricity coordinates 
 To determine whether transport deficits in the SC corresponded with areas of RGC soma 
loss in the retina, an overlay of SC transport maps onto coordinates of the SC retinotopic map 
was conducted as detailed previously (Lambert et al., 2011). These retinotopic maps follow the 
conventions of papers documenting electrophysiological characterization of the topography of 
visual projections to the SC (Siminoff et al., 1966; Drager and Hubel, 1976). Each topographic 
map indicates areas of SC receiving input from specific quadrants (superior, nasal, inferior, 
temporal) of the retina. 
 
Statistical methods 
 Group averages were calculated and compared in SigmaPlot (version 11.1, SYSTAT) 
using two-sided t-tests for all data passing Shapiro-Wilk normality tests. For data that did not 
pass Shapiro-Wilk normality, non-parametric Mann-Whitney Rank Sum tests were used. Error as 
reported in text and on bar graphs represents mean ± SEM.  
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Results 
Trpv1-/- mice exhibit a truncated Trpv1 gene 
 To confirm that all mice used for Trpv1-/- studies were of the correct genotype, I 
conducted PCR to verify gene ablation in Trpv1-/- mice. Agarose gels indicate a shift in PCR 
products produced from the same set of primers (Figure 2.5). PCR products from C57 mice 
appeared as a band at the expected size of 984 bp. Products from Trpv1-/- mice appeared as a 
band at the expected size of 600 bp. 
 
 
Figure 2.5. Confirmation of knockout in Trpv1-/- mice. Agarose gel showing PCR products 
from genotyping of several C57 and Trpv1-/- mice used in experiments. PCR reactions produced 
a 984 bp product for all C57 mice and a 600 bp product for all Trpv1-/- mice as expected. 
Correct genotype was verified for all animals involved in Trpv1-/- experiments. 
 
 
Trpv1-/- accelerates axonopathy in the optic projection 
We elevated intraocular pressure (IOP) in C57 and Trpv1-/- mice by microbead occlusion 
of aqueous fluid in the anterior chamber (Sappington et al., 2010; Chen et al., 2011). A single 
unilateral microbead injection elevated IOP by ~33% for just over 5 weeks (36 days), while IOP 
from saline-injected fellow eyes remained near baseline (~15 mmHg) for the duration of the 
experiment (Figure 2.6A). This elevation was significant in both C57 and Trpv1-/- mice (p < 
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0.001). Trpv1-/- had no significant effect on IOP for either control or experimental eyes 
compared to C57 mice (p ≥ 0.842; Figure 2.6B). 
 
 
Figure 2.6. Microbead-induced elevations in mouse intraocular pressure. A, Daily mean 
intraocular pressure in mmHg (IOP; n ≥ 20 measurements each day, mean ± SEM) for a 37 day 
period in cohorts of C57 vs. Trpv1-/- mice (n = 10 each) before (day 0) and following (days ≥ 1) 
a single unilateral injection of polystyrene microbeads (1.0 µl) into the anterior chamber. The 
fellow eye in each animal received an equivalent volume saline injection as internal control. B, 
Microbead eyes exhibited a significant increase in IOP following injection (mean ± SEM for 
days ≥ 1) compared to saline eyes in both C57 (19.77 ± 0.76 vs. 14.75 ± 0.65 mmHg) and Trpv1-
/- (19.79 ± 0.80 vs. 14.96 ± 0.72 mmHg) mice (* p < 0.001). Between the two cohorts, IOP was 
similar for both saline-injected (p = 0.842) and microbead-injected (p = 0.980) eyes. 
 
In naïve C57 mice, RGC axonal transport of cholera toxin B (CTB) injected intravitreally 
in both eyes (Figure 2.2A) reveals the dominant contralateral and lesser ipsilateral projections to 
the lateral geniculate nucleus (LGN; Figure 2.2B) and more distal superior colliculus (SC; Figure 
2.2C). Following the period of IOP elevation, the LGN projection (Figure 2.7A) from saline-
injected eyes in C57 and Trpv1-/- mice demonstrated intact CTB transport (Figure 2.7B), while 
the projection from the microbead-injected eyes demonstrated deficits in transport (Figure 2.7C). 
These deficits in CTB transport to the LGN in Trpv1-/- mice appeared more dramatic than those  
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Figure 2.7. Trpv1-/- exacerbates microbead-induced transport deficits to the LGN. A, Schematic 
illustrating unilateral elevation of IOP for 36 days by microbead occlusion followed by bilateral 
CTB tracing 48 hours before sacrifice. Deficits in transport (indicated by gray) are expected in 
large contralateral projections and small ipsilateral projections to both the dLGN and vLGN. 
Medial (M), dorsal (D), and rostral (R) orientations indicated. B,C, Coronal sections through 
LGN from C57 (top row) and Trpv1-/- mice (bottom row) following bilateral intravitreal 
injections of CTB (green). In LGN ipsilateral to microbead eye B, CTB signal from saline-
injected eye remains intact (solid white outline), while signal from microbead-injected eye shows 
deficits embedded in both dLGN and vLGN (dashed yellow outline). Deficits appear worse in 
Trpv1-/- LGN. In LGNs contralateral to microbead eye C, CTB signal from saline-injected eye is 
again intact (solid white outline). In the dLGN, CTB signal from microbead-injected eyes 
(yellow outlines) shows a range in deficits (dashed yellow). Once again, deficits appear worse in 
Trpv1-/- dLGN. The Trpv1-/- vLGN also appears to have less CTB signal. Scale = 200 µm in all 
images.  
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seen in C57. Similarly, while the SC projection (Figure 2.8A) from microbead-injected eyes in 
C57 and Trpv1-/- mice demonstrated transport deficits, CTB transport from the saline eye 
remained intact (Figure 2.8B). 
 Next we compared the spatial progression of transport deficits in the SC after microbead 
injection, since this distal-most target in the RGC projection demonstrates IOP-related transport 
deficits earliest (Crish et al., 2010). Following the period of microbead-induced IOP elevation, 
the SC of C57 mice demonstrated a partially intact retinotopic representation of axonal transport 
of CTB injected intravitreally (Figure 2.9A). Depletion of transport progressed in sectors 
extending from the peripheral edge of the map towards the representation of the optic disc, 
consistent with our previous studies using this model (Crish et al., 2010). While anterograde 
transport from saline-injected eyes was intact for both cohorts, the SC from microbead-injected 
eyes of Trpv1-/- mice often demonstrated a nearly complete retinotopic loss (Figure 2.9B). When 
quantified, each cohort exhibited a range in the magnitude of transport deficits with elevated 
IOP, as measured by the fraction of intact retinotopic map (Figure 2.10A). However, the range 
for Trpv1-/- mice was entirely below 50%, while most C57 SC were above this point (Figure 
2.10A). Accordingly, deficits in Trpv1-/- SC were twice as severe as in C57, with average intact 
transport of about 25% of the retinotopic map compared to just over 50% for C57 (Figure 
2.10B). 
In models of glaucoma, outright degeneration of RGC axons in the optic nerve is 
subsequent to dysfunction in anterograde axonal transport to central structures like the SC and 
LGN (Calkins, 2012). We found that with elevated IOP, cross-sections of C57 optic nerve 
demonstrated early signs of pathological progression such as degenerating axon profiles and 
diminished axon density (Figure 2.11A). Nerves from Trpv1-/- mice exhibited accelerated  
61 
 
 
Figure 2.8. Trpv1-/- exacerbates microbead-induced transport deficits to the SC. A, Schematic 
illustrating unilateral elevation of IOP for 36 days by microbead occlusion followed by bilateral 
CTB tracing 48 hours before sacrifice. Deficits in transport (indicated by gray) are expected in 
large contralateral projections and small ipsilateral projections to the SC. Medial (M), dorsal (D), 
and rostral (R) orientations indicated. B, Coronal sections through rostral pole of C57 (left) and 
Trpv1-/- (right) SC show intact CTB signal (green) in the SC contralateral to saline injection 
(white outline). CTB signal in the SC contralateral to microbead injection (dashed yellow 
outline) is reduced following 5 weeks of elevated IOP. In SC contralateral to microbead-
injection, CTB signal in ipsilateral projections (arrows) remain intact, as expected. Scale = 200 
µm in all images.  
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pathology, with the most extreme samples from the cohort accented by a pronounced increase in 
degenerating profiles, severely reduced axon density, and overt hypertrophy of astrocyte 
processes (Figure 2.11B). Nerves from the saline eyes of the two cohorts appeared similar. 
Using custom programmed routines, we determined average axon density from sections 
of optic nerve. Axon density in nerves from saline-injected C57 eyes ranged from 384,000-
538,000 axons/mm
2
 (Figure 2.12A), consistent with previous studies (Sappington et al., 2010). 
Microbead elevation shifted this range to 277,000-477,000 axons/mm
2
. Trpv1-/- had no effect on 
axon density in the saline nerve (range of 356,000-521,000 axons/mm
2
), but, like transport to the 
SC, exacerbated the reduction caused by elevated IOP. Nerves from Trpv1-/- microbead eyes had 
axon densities that ranged from 67,000-331,000 axons/mm
2
 (Figure 2.12A). On average, 
elevated IOP reduced axon density in C57 optic nerves by 14% compared to saline nerves (p = 
0.029; Figure 2.12B). Trpv1-/- microbead nerves exhibited a 47% decrease in density compared 
to their saline counterparts (p < 0.001; Figure 2.12B). This decrease in axon density was 
accompanied by a small decrease (about 14%) in cross-sectional nerve area only in Trpv1-/- mice 
(Figure 2.12C). Finally, we estimated the total number of axons in each nerve by multiplying 
axon density by nerve cross-sectional area. This yielded a range of 32,000-54,000 axons in 
nerves from saline eyes from both cohorts (not shown), again consistent with previous studies 
(Sappington et al., 2010). The corresponding mean was 41,659 axons for C57 (± 2700) and 
42,990 for Trpv1-/- (± 1917; Figure 2.12D). On average, elevated IOP reduced the number of 
axons in C57 optic nerves by 17% compared to saline nerves (p = 0.04; Figure 2.12D). Again, 
the Trpv1-/- microbead nerves exhibited a far worse effect, with an average 53% loss of axons (p 
< 0.001; Figure 2.12D). 
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Figure 2.9. Trpv1-/- exacerbates deficits in anterograde axonal transport. A, Top row: coronal 
sections through superior colliculus (SC) following intravitreal injection of cholera toxin B 
(CTB; green) into saline- and microbead-injected eyes of C57 mice. Microbead-induced IOP 
elevation (see Figure 1) induced deficits in anterogradely transported CTB (dotted lines). Bottom 
row: retinotopic maps reconstructed from serial sections of SC with optic disc gap indicated 
(circles). Density of signal from transported CTB ranges from 0% (blue) to 50% (green) to 100% 
(red). Medial (M) and rostral (R) orientations indicated. B, Top row: sagittal SC sections from 
Trpv1-/- mice with microbead-induced IOP elevations show worse deficits in CTB transport 
compared to C57. Corresponding retinotopic maps (bottom row) demonstrate nearly complete 
loss of CTB transport. OD: optic disc representation (no RGCs). Scale = 500 µm for A,B. 
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Trpv1-/- influences RGC survival in the retina 
RGC somal degeneration in the retina follows optic nerve axonopathy in both chronic 
and inducible models of glaucoma, including the microbead model used here (Calkins, 2012). 
The five week duration of IOP elevation in our cohorts did not induce large-scale RGC body loss 
in either mouse strain (Figure 2.13A,B), though accumulation of phosphorylated 
neurofilaments—indicative of a deficit in anterograde transport—tended to be worse for the 
Trpv1-/- (Figure 2.13C). We have previously demonstrated in both chronic and inducible models 
that initial deficits in anterograde transport are not due to reduced uptake of CTB by RGCs 
(Crish et al., 2010; Lambert et al., 2011; Dapper et al., 2013). For example, in the Trpv1-/- 
mouse with 15% intact transport of CTB to the SC with IOP elevation (Figure 2.10A), the 
number of RGCs labeled by CTB uptake (3842 ± 271 mm
2
) was the same as that labeled for 
phosphorylated neurofilaments (4123 ± 214 mm
2
; p = 0.423). Similarly, RGC uptake of CTB is 
not affected by Trpv1-/- in either saline or microbead retina—nearly every RGC contains label 
(Figure 2.13B). We therefore cannot attribute the transport deficits we see in the colliculus to an 
apparent difference in CTB uptake between cohorts. 
Moreover, when quantified across retinal quadrants, for most distances from the optic 
nerve head, neither cohort showed significant RGC body loss (Figure 2.14). At most locations, 
the ratio of RGC body density in the two eyes did not differ from unity, though there was a 
certain degree of variability. However, in microbead retinas from Trpv1-/- mice, accelerated loss 
was observed in the nasal quadrant; the most pronounced loss was nearest the optic disc with 40 
± 7% reduction compared to the saline eye (p = 0.03). At the same location, reduction in the C57 
microbead retina was 24 ± 11%, which was not significant (p = 0.20). Thus, in both the optic 
projection and the retina, Trpv1-/- accelerates RGC degeneration associated with elevated IOP. 
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Figure 2.10. Quantification of anterograde transport in the superior colliculus. A, Fraction of the 
retinotopic map with intact RGC axonal transport (defined by ≥70% CTB signal) to individual 
C57 and Trpv1-/- saline (n = 10 and 8, respectively) and microbead (n = 10 and 10, respectively) 
superior colliculi. B, Transport of CTB from saline eyes was near 100% and similar for C57 
(93.8 ± 2.5%) and Trpv1-/- (90 ± 3.5%) cohorts (mean ± SEM; p = 0.46). Intact transport in SC 
following IOP elevation was reduced in both cohorts compared to the saline eye (*, p < 0.001), 
but the decrease in Trpv1-/- (26.6 ± 4.0%) was twice as severe as in C57 (51.7 ± 4.1%; †, p < 
0.001). Legend as in B. 
 
The results in Figure 2.14 also complement our previous work in which rats with elevated 
IOP for a similar duration exhibited reduced RGC density in the nasal quadrant (Lambert et al., 
2011). Within the visual system, perception dictates that neuronal projections are precisely 
organized so that a continuous retinotopic representation of the space is retained (Chklovskii and 
Koulakov, 2004). In terms of RGCs, axons projecting from the retina onto the SC form a precise 
retinotopic map, which can be used to determine where in the retina deficits in transport 
originate. Taking advantage of this, we transformed our retinotopic maps (Figure 2.9) using 
retinal quadrant and eccentricity coordinates for rodents (Figure 2.15; Siminoff et al., 1966; 
Drager and Hubel, 1976). Deficits in axonal transport to the SC from microbead-injected eyes in 
C57 and Trpv1-/- mice tended to progress from or spread to the nasal quadrant of the retina 
(Figure 2.15). Interestingly, the nasal quadrant was where we observed a significant loss of RGC 
66 
 
bodies in Trpv1-/- retinas from microbead-injected eyes (Figure 2.14). This indicates that the 
retinotopic pattern of degeneration is conserved in this model. 
 
 
Figure 2.11. Trpv1-/- mice exhibit more severe optic nerve pathology following elevated IOP. A, 
Cross-sections of C57 optic nerve from saline and microbead eyes. Microbead-induced elevated 
IOP yielded a modest reduction in the packing density of intact axons and increased incidence of 
degenerating axonal profiles (red arrowheads). B, Cross-section through Trpv1-/- optic nerve 
from microbead eye shows severely diminished axon packing, overt gliosis (red arrows), and far 
more degenerating profiles compared to C57 nerves (red arrowheads). Saline eye nerves from the 
two cohorts appear similar. Scale = 10 µm for A,B.  
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Figure 2.12. Quantification of axon loss in the optic nerve. A, Density of intact axons in cross-
sections through individual C57 and Trpv1-/- saline (n = 10 and 9, respectively) and microbead 
(n = 9 and 7, respectively) optic nerves quantified from cross-sections as shown in Figure 4. B, 
Mean axon density (± SEM) in C57 and Trpv1-/- optic nerves. Diminished density from 
microbead-induced IOP elevation in Trpv1-/- nerves is more than twice that of C57 nerves (†, p 
< 0.001). An * indicates significance for microbead compared to corresponding saline nerve (*, p 
= 0.001 for C57; p < 0.001 for Trpv1-/-). C, Cross-sectional area (mean ± SEM) of Trpv1-/- optic 
nerves shrinks with elevated IOP compared to saline eye (*, p = 0.005). D, Number of axons 
(mean ± SEM) calculated as product of nerve area and axon density. Trpv1-/- nerves have nearly 
twice the loss compared to C57 nerves with elevated IOP (†, p < 0.001), though both groups 
have fewer axons compared to saline nerves (*, p = 0.03 for C57 and 0.04 for Trpv1-/-). Number 
of axons in saline nerves was similar in two cohorts (p = 0.70). Legend applies to A-D. 
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Figure 2.13. Progression to RGC body loss accelerated in Trpv1-/- mice. Confocal micrographs 
of C57 A, and Trpv1-/- B, retinas show RGCs labeled both by CTB uptake (red) and with 
antibodies against phosphorylated neurofilaments (green). In both cohorts, there is little apparent 
change in cell number with microbead-induced IOP elevations. Importantly, nearly every RGC is 
labeled by both markers, indicating intact RGC uptake of CTB. C, C57 (left) and Trpv1-/- (right) 
retinal peripheries show accumulation of phosphorylated neurofilaments in RGC dendritic arbors 
(arrowheads) with IOP elevation. Tendency is more robust in Trpv1-/- retina, with axonal 
accumulation as well (dashed lines). Scale = 20 µm for A-C. 
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Figure 2.14. Quadrant-specific RGC body loss in Trpv1-/-. Density of RGC bodies (RGCs/mm
2
) 
labeled for phosphorylated neurofilaments (cells/mm
2
) expressed as the ratio of microbead to 
saline retina (means ± SEM) for increasing eccentricities from the optic disc. At each location, 
cells were scored as described above (see Methods) in images of 0.101 mm
2
 in area (n = 5 retina 
each). For superior, inferior and temporal quadrants, neither cohort had significant RGC body 
loss at any eccentricity (p ≥ 0.08). In the nasal quadrant, Trpv1-/- microbead retina showed 
moderate (20-40%) accelerated loss compared to saline at 0.75 and 2.25 mm eccentric (*, p = 
0.03 and 0.05, respectively). 
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Figure 2.15. Microbead-induced anterograde transport deficits in SC are retinotopically 
sectorial. Reconstructed CTB transport maps transformed into retinal quadrant and eccentricity 
coordinates as specified by Siminoff et al. (1966) and Drager and Hubel (1976). Retinal 
quadrants are indicated by abbreviation: inferior (I), nasal (N), superior (S), and temporal (T). A, 
Maps of superior colliculi from C57 saline control eyes are complete (approximately 98%) with 
optic disc indicated (*). B, Transport deficits (shaded regions) in colliculi from C57 microbead-
injected eyes with intact transport of 72%, 57%, and 32% (left to right, respectively). Deficits in 
nasal quadrant were moderate (middle) to severe (right). C, Maps of colliculi from Trpv1-/- 
saline control eyes are complete (95-99%). D, Transport deficits from Trpv1-/- microbead-
injected eyes exhibited a spread to nasal quadrant in eyes with both moderate (42% intact, left) 
and severe (32% and 19% intact, middle and right, respectively) deficits. 
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Discussion 
TRPV1 is known to influence neuronal physiology and synaptic function, as 
demonstrated by neurophysiological changes in Trpv1-/- mice (Marsch et al., 2007; Gibson et al., 
2008; Li et al., 2008; Maione et al., 2009; Chavez et al., 2010; Grueter et al., 2010). Here, we 
show that with elevated pressure in the eye, the absence of functional TRPV1 accelerates 
neurodegeneration. An early characteristic of neurodegeneration in glaucoma is degradation of 
active transport from the retina to the colliculus, which occurs prior to outright axon 
degeneration in the optic nerve (Crish et al., 2010; Lambert et al., 2011; Dapper et al., 2013). 
After a five-week period of an equivalent elevation in IOP (33%; Figure 2.6), both deficits in 
anterograde transport to the colliculus (Figures 2.9 and 2.10) and degeneration of axons in the 
optic nerve (Figures 2.11 and 2.12) were about twice as severe in Trpv1-/- than in age-matched 
C57 mice. Similar to other neurodegenerative diseases, axonopathy is among the earliest 
pathogenic events in glaucoma, with RGC body loss in the retina following later (Whitmore et 
al., 2005; Calkins, 2012; Howell et al., 2012). This period is especially pronounced in models 
utilizing modest elevations in IOP, including the microbead model used here (Calkins, 2012; 
Dapper et al., 2013). Thus, while RGC body drop-out was hardly detectable in C57 retina, 
Trpv1-/- retina demonstrated significant loss in the nasal quadrant, especially in the region of 
normally highest RGC density near the optic nerve head (Figure 2.14). This extra susceptibility 
of the nasal quadrant (Figure 2.15), while not yet understood, is consistent with results from 
other rodent models (Lambert et al., 2011). 
The nasal quadrant of the C57 mouse retina exhibits a high density of RGC somas across 
all eccentricities, whereas the temporal, superior, and inferior quadrants exhibit a gradient of 
somal density (Jeon et al., 1998). For all retinal quadrants except for the nasal quadrant, somal 
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density increases moving from the periphery (furthest from the optic disc) to the center (closest 
to the optic disc). Within the nasal quadrant, RGC density in the periphery is approximately 
equal to the density at more central eccentricities, so this region has an overall higher density of 
RGC somas (Jeon et al., 1998). Knowing this specific difference within the nasal quadrant may 
be useful for understanding why earliest pathological signs are present in this quadrant first. 
Perhaps this is due to local increases in extracellular factors that may accompany the earliest 
stages of RGC dysfunction and degeneration. It is known that mechanical strain, as is expected 
in glaucoma, causes RGCs to release ATP through pannexin channels, and that this extracellular 
ATP, in turn, acts on P2X7 receptors that can cause pro-apoptotic Ca
2+
 influx into RGCs (Zhang 
et al., 2005b; Hu et al., 2010; Xia et al., 2012; Sugiyama et al., 2013). Essentially, stressed RGCs 
may release factors like ATP into the extracellular environment, and these factors may then act 
locally on P2X7 receptors of nearby RGCs. If these cells are more densely packed, it is possible 
that factors released from a stressed RGC have a better chance of affecting nearby RGCs simply 
due to increased proximity. Areas of retinal tissue with higher RGC density, such as the nasal 
region, may therefore exhibit higher levels of apoptosis. This may explain why in Trpv1-/- mice 
we observe somal loss in the nasal quadrant before any of the other quadrants. 
It is also important to consider trends from data that, though statistically non-significant, 
may be biologically relevant. In the nasal quadrant of C57 mice, RGC somal density exhibits 
near-significant reduction following pressure elevation (Figure 2.14). This reduction may be 
biologically relevant, as we see this trend in Trpv1-/- mice, which exhibit an accelerated 
pathology compared to C57 mice. Likewise, following pressure elevation in C57 mice, RGC 
density within the superior quadrant exhibited a non-significant decrease in the retinal periphery. 
These changes were not observed in the Trpv1-/- mice, possibly indicating a protective effect of 
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Trpv1-/- in this quadrant. It is likely that the effects of TRPV1-mediated Ca
2+
 entry are very 
dependent on the context and local milieu of the RGCs. For example, not only could activation 
of TRPV1 cause pro-apoptotic Ca
2+
 influx in RGCs (Sappington et al., 2009), but it could also 
activate glial NFκB signaling, which has been linked to induction of oxidative stress (Neufeld 
and Liu, 2003; Sappington and Calkins, 2008). If TRPV1 contributes to this type of signaling 
within the superior quadrant, then Trpv1-/- may be protective. This is not entirely unexpected, as 
it has been observed that different spatially-organized signaling microenvironments exist within 
glaucomatous retinas (Sims et al., 2012). Such microenvironments may exist for TRPV1-related 
signaling and relevant stressors, which may in part explain why we see differences in stress 
response and pathology when comparing between retinal quadrants. It is also possible that these 
soma counts are affected by our use of an antibody against phosphorylated neurofilaments to 
identify RGC somas. This antibody labels axons of RGCs in addition to their somas, and axonal 
labeling can sometimes obstruct the view of cell bodies, especially at eccentricities closer to the 
optic disc. Future studies could use a marker such as Brn3 protein, which only labels RGC somas 
and may provide a more accurate readout of somal density. Overall, there are many explanations 
that can be considered for these statistically non-significant results, but they do seem to indicate 
the importance of understanding TRPV1 signaling microenvironments within the retina. 
We propose that TRPV1 plays an early, Ca
2+
-dependent role in detecting stress 
associated with elevated pressure in glaucoma, in order to mediate a compensatory response to 
counter disease progression. In isolated RGC cultures exposed to elevated hydrostatic pressure in 
vitro, the pressure stressor is acute, and TRPV1 activation is sufficient to induce an apoptotic 
increase in intracellular Ca
2+
 (Sappington et al., 2009). In the intact system, the same activation 
by a modest, chronic stressor would seem to initiate protective cascades that may in part boost 
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RGC excitation. Thus, progression is accelerated with Trpv1-/-, in which the absence of TRPV1 
abolishes an intrinsic physiological mechanism that enhances RGC excitatory signaling under 
conditions that stress the neuron, especially the axon. This model is consistent with other in vivo 
results in which pharmacological antagonism of TRPV1 ablated the protection afforded by an 
anandamide analogue on RGC survival with ischemic-reperfusion injury induced by acutely 
elevated IOP (Nucci et al., 2007b). Our hypothesis is also supported by recent work showing that 
the related TRPC6 channel is protective in a model of retinal ischemia/reperfusion injury (Wang 
et al., 2010). 
We do not yet understand all possible mechanisms through which TRPV1 could counter 
neuronal stress, though both neuronal and glial mechanisms are likely (Ho et al., 2012). TRPV1 
can be activated and/or sensitized either directly by mechanical stress or by endogenous ligands 
like endocannabinoids and growth factors (Straiker et al., 1999; Stamer et al., 2001; Zhang et al., 
2005a). In addition to RGCs, TRPV1 is expressed in both astrocytes and microglia of the retina 
(Leonelli et al., 2009; Sappington et al., 2009). Activation in retinal microglia is coupled to 
release of interleukin-6, which is protective of isolated RGCs exposed to elevated pressure 
(Sappington et al., 2006; Sappington and Calkins, 2008). The endogenous cannabinoid 
anandamide is a ligand for both TRPV1 and the cannabinoid type 1 receptor and is known to 
protect against ischemic injury and excitotoxicity (Kim et al., 2007). TRPV1 and the anandamide 
precursor enzyme NAPE phospholipase D are expressed in the RGC projection to the colliculus 
(Maione et al., 2009), the primary target for RGCs in the rodent visual system. Thus, TRPV1 
could help counter progression through axonal mechanisms outside of the retinal milieu. 
With stress, neuronal TRPV1 is upregulated and undergoes translocation to the plasma 
membrane, where it increases post-synaptic neurite activity and survival (Zhang et al., 2005a; 
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Biggs et al., 2008; Goswami et al., 2010; Schumacher and Eilers, 2010). Once translocated, 
TRPV1-gated Ca
2+
 promotes spontaneous excitation and potentiates post-synaptic responses to 
glutamate (Marinelli et al., 2003; Xing and Li, 2007; Medvedeva et al., 2008; Jiang et al., 2009; 
Peters et al., 2010). Phosphorylation promotes sensitization, continued translocation, and 
increased depolarization (Van Buren et al., 2005). TRPV1 can become desensitized by 
dephosphorylation via the calmodulin-dependent protein phosphatase, calcineurin, or by re-
internalization (Mohapatra and Nau, 2005). Together with these findings, our results suggest that 
TRPV1 could contribute to RGC survival in response to stress or injury by utilizing both 
extrinsic and intrinsic signaling mechanisms. 
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CHAPTER 3 
 
ELEVATED PRESSURE INCREASES RETINAL TRPV1 AND ITS RELATION TO 
GANGLION CELL SYNAPSES
3
 
 
Introduction 
In the retina, TRPV1 has been linked to RGC survival in vivo in response to stressors 
such as transient ischemic insult induced by acutely elevated IOP (Nucci et al., 2007b) and 
NMDA-induced neuronal injury (Sakamoto et al., 2014). These studies and our data (Ward et al., 
2014) demonstrate the relevance of TRPV1 in RGC survival; however, our understanding of how 
TRPV1 functions depends on our knowledge of how the protein responds to stressors. To 
appreciate how TRPV1 mediates its effects during injury, we must first determine where the 
channel is localized within the retina and how glaucomatous stress influences its expression and 
localization. 
Previous studies have demonstrated expression of TRPV1 in both non-mammalian 
(Zimov and Yazulla, 2004, 2007) and mammalian (Sappington and Calkins, 2008; Leonelli et al., 
2009; Sappington et al., 2009; Martinez-Garcia et al., 2013) retinal tissue. Immunolabeling for 
TRPV1 protein in the rabbit retina indicates TRPV1 is expressed across all nuclear and synaptic 
layers of the retina (Martinez-Garcia et al., 2013). TRPV1 expression in the rat retina appears 
more restricted than in the rabbit retina; however, expression is still widespread. Immunolabeling 
for TRPV1 protein and in situ hybridization of Trpv1 mRNA in rat retinal tissue indicates that 
TRPV1 can be found in the nerve fiber, ganglion cell, inner plexiform, inner nuclear, and outer 
plexiform layers (Sappington et al., 2009). Additionally, TRPV1 has been localized to retinal 
                                                          
3
 Portions of this chapter were published as Ward NJ (2012) TRPV1 and the intrinsic neuronal 
response to stress. Vanderbilt Rev Neurosci 4:108-113. 
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glia (i.e., astrocytes, microglia, and Müller glia), which are found in several different retinal 
layers (Sappington and Calkins, 2008; Leonelli et al., 2009; Sappington et al., 2009). TRPV1 
localization in C57 mice is similar to that of rats, and the protein is found in all retinal layers 
associated with each cellular compartment of the RGC—the cell body, dendrites, and axon 
(Sappington et al., 2009). 
Localization studies of TRPV1 in the retinal plexiform layers that contain synapses 
indicates a potential synaptic function for the protein (Zimov and Yazulla, 2004; Leonelli et al., 
2009; Sappington et al., 2009; Martinez-Garcia et al., 2013). Synaptic localization of TRPV1 in 
the retina is not a surprising idea, as TRPV1 protein was identified in synaptosomal fractions 
isolated from primary cultures of cortical neurons (Goswami et al., 2010). Primary cultures of 
RGCs exhibit expression of TRPV1 throughout their neurites, including node-like clusters of 
TRPV1 that may indicate synaptic specializations (Sappington et al., 2009). Likewise, previous 
studies within the CNS have localized TRPV1 to postsynaptic dendritic spines by using pre-
embedding immunogold labeling imaged by high resolution electron microscopy (Puente et al., 
2011; Puente et al., 2014). These studies indicate that in both the hippocampus and extended 
amygdala, TRPV1 exhibits perisynaptic and extrasynaptic localization. The number of TRPV1-
associated immunoparticles was greatest in the perisynaptic membrane region immediately 
abutting the postsynaptic density, and gradually decreased as distance from the postsynaptic 
density increased. Localization of TRPV1 to the inner plexiform layer of the retina, where RGC 
receive synaptic input at postsynaptic dendritic sites, suggests that TRPV1 may affect dendritic 
or synaptic function in these neurons (Sappington et al., 2009; Martinez-Garcia et al., 2013). 
Currently, TRPV1 has not been associated with synaptic structures in the retina. Here, we 
examine TRPV1 expression alongside PSD-95 and MAP2 proteins to better understand its 
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localization. PSD-95 is a scaffolding protein found in postsynaptic specializations on dendrites, 
and it associates with receptors and cytoskeletal elements at these synaptic structures (El-
Husseini et al., 2000). Within the retina, PSD-95 has previously been used to identify 
postsynaptic specializations found on RGC dendrites (Stevens et al., 2007). We also examined 
MAP2 (microtubule associated protein 2), which is a component of microtubule structures in 
neuronal dendrites. Within the retina, MAP2 has previously been used to identify RGC dendritic 
structures within the inner plexiform layer of the retina (Okabe et al., 1989). The following 
studies aim to determine whether TRPV1 protein levels and localization within the retina are 
affected by elevated IOP. Additionally, we sought to examine how RGC dendrites and synapses 
respond to pressure, and if TRPV1 may be associated with these responses.  
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Materials and Methods 
Induction of ocular hypertension by microbead occlusion 
Intraocular pressure (IOP) was acutely elevated in 3-month-old C57 mice by microbead 
occlusion of aqueous flow as described previously (Sappington et al., 2010). All procedures and 
IOP measurement methods followed those described in Chapter 2 Methods. For qPCR studies, 
cohorts of mice were sacrificed by cervical dislocation at 1 week, 2 weeks, 3 weeks, and 5 weeks 
after microbead injection, and each cohort included 4 animals. For immunohistochemistry 
studies, cohorts of mice were sacrificed at 4 days, 1 week, 3 weeks, 5 weeks, or 7 weeks after 
microbead injection, and each cohort included between 3 and 5 animals. 
 
Tissue preparation 
For mice used in qPCR studies, fresh retinal tissue was dissected from both saline- and 
microbead-injected eyes and was stored at -80ºC prior to RNA extraction. For mice used in 
immunohistochemistry studies, all animals were transcardially perfused with phosphate buffered 
saline (PBS) followed by 4% paraformaldehyde (PFA) in PBS and tissue was harvested. Eyes 
were enucleated and submitted to the Vanderbilt Eye Institute Histology Core for sectioning. 
Eyes were processed, paraffin embedded, and the middle two-thirds of the eyes were cut into 6-
10 µm thick sections. 
 
Quantitative PCR 
RNA was extracted from retinas of microbead-injected C57 mice as previously described 
(Hanna and Calkins, 2006; Crish et al., 2013). Tissue was incubated overnight in lysis buffer (10 
mM Tris/HCl, pH 8.0; 0.1 mM EDTA, pH 8.0; 2% SDS, pH 7.3; and 500 µg/ml proteinase K 
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(Clontech Labs, Mountain View, CA)) before RNA extraction with Trizol (Invitrogen) and 10 µg 
glycogen used as an RNA carrier. RNA purity and concentration were determined with a 
NanoDrop 8000 spectrophotometer (Thermo Scientific, Wilmington, DE). Samples (1 µg) were 
treated with DNase (Invitrogen) and cDNA was synthesized (Applied Biosystems reagents, 
Foster City, CA). We performed qPCR as previously described (Crish et al., 2013) using an ABI 
PRISM 7300 Real-Time PCR System and FAM dye-labeled gene-specific probes for Trpv1 
(Applied Biosystems). ABI software (SDS v1.2) was used to automatically determine cycling 
conditions and threshold values. Using 18S rRNA as an endogenous control, relative Trpv1 
product quantities were measured at least in triplicate and determined using the 2
ΔΔCt
 analysis 
method (Livak and Schmittgen, 2001). 
 
Immunolabeling of retinal paraffin sections 
Paraffin sections were deparaffinized by incubation at 60ºC for 1 hour. Slides were rinsed 
in two separate washes of xylene for 10 min. Sections were rehydrated using an ethanol series 
comprised of 10 minute washes each in freshly-prepared 100% EtOH (twice), 95% EtOH, 70% 
EtOH, and ddH2O. Tissue was washed in PBS for 5 min with shaking, excess PBS was removed 
by blotting with a Kimwipe, and boxes were traced around all sections with a hydrophobic 
PapPen to prevent solution runoff. Non-specific binding was blocked by incubating sections in 
5% normal donkey serum (NDS) plus 0.1% Triton-X 100 diluted in PBS for 2 hours at room 
temperature. 
Primary antibodies were diluted to recommended concentration in a solution of 3% NDS 
plus 0.1% Triton-X 100 diluted in PBS. Primary antibodies used in these studies were rabbit 
anti-TRPV1 (1:100, Neuromics), mouse anti-PSD-95 (1:200, Millipore), rabbit anti-MAP2 
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(1:200, Cell Signaling Technology), and goat anti-ChAT (1:100, Millipore). Blocking buffer was 
drained from sections, primary antibody solution was applied to tissue, and all slides were 
incubated for 3 days at 4ºC in a humidified chamber. For control experiments in which no 
primary antibody was used, this same solution was used but no antibody was included. Slides 
were drained of primary antibody solution and washed in PBS 3 times for 10 minutes at room 
temperature while shaking. Secondary antibodies were diluted 1:200 in a solution of 1% NDS 
plus 0.1% Triton-X 100 diluted in PBS. Secondary antibodies used in this study were raised in 
donkey and conjugated to Alexa-488 or Cy3 (Jackson Immunoresearch). Secondary antibody 
solution was applied to tissue sections and incubated for 2 hours at room temperature in the dark. 
Slides were drained of secondary antibody solution and washed in PBS 4 times for 10 minutes 
followed by ddH2O for an additional 10 minutes. Slides were optionally counterstained for cell 
nuclei using 4’,6–diamidino–2–phenylindole dihydrochloride (DAPI). DAPI diluted 1:100 in 
ddH2O was applied to sections and incubated for 5 min at room temperature in the dark. Excess 
DAPI was drained and slides were washed 5 times in PBS for 5 min with shaking. Tissue was 
mounted using Fluoro-Mount aqueous mounting media, and slides were coverslipped and sealed 
using Cytoseal. 
 
Imaging and quantification of immunohistochemistry 
Following immunolabeling, vertical paraffin sections of retina were imaged using an 
Olympus FV-1000 inverted confocal microscope. For experiments in which intensity 
comparisons were made, microscope settings (e.g., laser intensity, pinhole size, exposure time) 
were kept consistent for all slides during the entirety of the imaging session. Using DAPI 
labeling as a reference point for all nuclear layers of the retina, ImageJ software (National 
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Institutes of Health, Bethesda, MD) was used to outline specific retinal layers. Fluorescent 
intensity of immunolabeled proteins was determined within outlined areas and averaged over the 
selected area of pixels. Using FluoView software (Olympus, Center Valley, PA), colocalization 
of TRPV1 and PSD-95 was examined by using Z-stacked micrographs through multiple optical 
planes of retinal tissue. To examine potential synaptic localization of TRPV1, studies were 
conducted specifically focusing on the inner plexiform layer. 
 
Statistical methods 
 Group averages were calculated and compared in SigmaPlot (version 11.1, SYSTAT) 
using two-sided t tests for all data passing Shapiro-Wilk normality tests. For data that did not 
pass Shapiro-Wilk normality, non-parametric Mann-Whitney Rank Sum tests were used. For 
data presented as ratios, comparisons versus unity (hypothesized mean = 1) were conducted 
using one-sample t-tests. Error as reported in text and on bar graphs represents mean ± SEM. 
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Results 
Regulation of Trpv1 transcript levels following microbead-induced IOP elevation 
 To examine whether IOP elevation induces changes in Trpv1 transcript levels, we 
injected C57 mouse eyes with microbeads to block aqueous fluid outflow (Sappington et al., 
2010; Chen et al., 2011). Microbead injection was used to elevate IOP in these mice for 1, 2, 3, 
and 5 weeks (n = 4 animals per timepoint, Figure 3.1A). Post-injection IOPs averaged for all 
animals indicate an approximately 22% elevation in microbead-injected eyes compared to 
contralateral eyes injected with an equivalent volume of saline. Pressure elevation in microbead-
injected eyes was significant when compared to saline-injected eyes (p ≤ 0.05; Figure 3.1B). 
 
 
Figure 3.1. Microbead-induced IOP elevation for animals used in Trpv1 transcript qPCR. A, 
Measurements of IOP taken from C57 mice injected with microbeads. Baseline IOPs (Day 0) 
were measured prior to injection. Each animal received an injection of microbeads in one eye 
and an equivalent volume of saline in the contralateral eye. Each line represents IOPs of animals 
from cohorts sacrificed at 1-, 2-, 3-, or 5-week timepoints following injection (n = 4 animals at 
each timepoint). B, Averaged IOP measurements for C57 animals for all days post-injection 
(Days ≥1). *, p ≤ 0.05. 
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Microbead:saline ratios of retinal Trpv1 transcript levels collected at 1, 2, 3, and 5 weeks 
indicated no significant changes from unity at these timepoints (Figure 3.2). Although no 
significant changes were discovered in whole tissue, a trend toward reduced Trpv1 expression at 
later timepoints may indicate a delayed downregulation of Trpv1 transcript following pressure 
elevation. 
 
 
Figure 3.2. Trpv1 transcript levels following microbead-induced pressure elevation. C57 mice 
were injected with microbeads to elevate intraocular pressure. At 1, 2, 3, and 5 weeks following 
injection, whole-retinal qPCR was conducted to measure Trpv1 transcript levels by 2
ΔΔCt
 
analysis. Microbead eye:saline eye Trpv1 transcript level ratios were calculated for each group (n 
= 4 animals per timepoint). All groups non-significant when compared to unity (red line). 
 
TRPV1 protein levels increase transiently in response to IOP elevation  
Significant changes in Trpv1 transcript levels may have been excluded by our choice of 
timepoints for qPCR quantification (Figure 3.2), so we looked at protein expression using both 
earlier and later timepoints. Microbead injection was used to elevate IOP in C57 mice, which 
were sacrificed for histological tissue preparation at 4-day, 1-, 3-, 5-, and 7-week timepoints (n =  
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Figure 3.3. Microbead-induced IOP elevation for animals used in histological experiments. A, 
Measurements of IOP taken from C57 mice injected with microbeads. Baseline IOPs (Day 0) 
were measured prior to injection. Each animal received an injection of microbeads in one eye 
and an equivalent volume of saline in the contralateral eye. IOP was monitored in microbead- 
and saline-injected mice for 4-day, 1-, 3-, 5-, or 7-week exposures prior to sacrifice (n = 3-5 
animals per timepoint). B, Averaged IOP measurements for C57 animals for all days post-
injection (Days ≥1). *, p ≤ 0.001. 
 
3-5 animals per timepoint, Figure 3.3A). Post-injection IOPs averaged for all animals indicate an 
approximately 34% elevation in microbead-injected eyes compared to contralateral eyes injected 
with an equivalent volume of saline. Pressure elevation in microbead-injected eyes was 
significant when compared to saline-injected eyes (p ≤ 0.001; Figure 3.3B). 
Retinal sections from C57 mice with 4-day, 1-, 3-, 5-, and 7-week IOP elevations 
demonstrated TRPV1 expression that was apparent in multiple retinal layers (Figure 3.4), as 
expected (Zimov and Yazulla, 2004, 2007; Sappington and Calkins, 2008; Leonelli et al., 2009; 
Sappington et al., 2009; Martinez-Garcia et al., 2013).  Across most retinal sections from saline-
injected eyes, TRPV1 exhibits membranous localization in nuclear layers (GCL, INL, ONL), 
punctate labeling in synaptic layers (IPL, OPL), and diffuse labeling within the unmyelinated 
portion of the RGC axons (NFL). At early, 4 day timepoints for both saline- and microbead- 
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Figure 3.4. TRPV1 protein levels transiently increase following IOP elevation. Vertical sections 
of C57 mouse retinas immuno-labeled for TRPV1 protein. TRPV1 intensity transiently increases 
in retinas from microbead-injected eyes, including layers that include the RGC cell body (GCL) 
and dendrites (IPL). GCL: ganglion cell layer, IPL: inner plexiform layer. 
 
injected eyes, TRPV1 localization within the RGCs in the ganglion cell layer appeared diffuse 
within the cell soma and membrane.  In microbead-injected eyes, qualitative assessment of 
TRPV1-associated fluorescence levels indicate a transient increase in TRPV1 following 1 week 
of elevated IOP. At this 1 week timepoint, TRPV1 intensity appears to be increased in layers 
associated with the RGC membrane and dendrites compared to saline-injected control eyes. 
TRPV1 expression was apparent throughout the retina; however, we were interested in 
RGC-specific expression based on our knowledge of its influence on RGC survival (Ward et al., 
2014). Quantification of average fluorescent pixel intensity in each RGC-associated region of the 
retina was used to determine TRPV1 levels in specific retinal layers. The microbead:saline ratios 
of TRPV1 expression for each of these layers indicated that there was a significant increase in 
TRPV1 within the inner plexiform layer at 1 week post-injection (Figure 3.5). Increases in 
TRPV1 protein levels were transient, and levels exhibited a gradual decrease out to the 7-week 
timepoint. 
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Figure 3.5. Microbead-induced IOP elevation transiently increases TRPV1 protein levels. Ratio 
of fluorescent intensity (microbead:saline) of immuno-labeled TRPV1 in sections of vertical 
retinal tissue. All retinal layers exhibited a trend toward transient elevation at 1 week, which was 
significant for the inner plexiform layer (*, p = 0.037, n = 3-5 animals per timepoint). 
 
Modulation of dendritic and synaptic protein levels by elevated IOP 
 Based on immunohistochemical detection of TRPV1 in the inner plexiform layer (IPL; 
Figure 3.4), which includes dendrites of RGCs, we wanted to examine if changes in TRPV1 
coincided with changes in dendritic and synaptic protein levels in the IPL. To determine if 
changes observed for TRPV1, MAP2, and PSD-95 expression were not due to tissue quality, 
non-specific binding of antibodies, or technical issues, we performed negative and positive 
controls using tissue from our time course animals. For negative control slides, I used the 1week 
timepoint, where TRPV1 labeling intensity was the strongest. As a negative control, no primary 
antibody was used in the staining protocol, and no non-specific binding of secondary antibody 
was observed in our tissue (Figure 3.6A). As a positive control, an antibody against choline 
acetyltransferase (ChAT) protein was used to show that our immunolabeling protocol yields 
specific binding. ChAT labeling is enriched at two synaptic layers within which cholinergic  
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Figure 3.6. Controls for immunohistochemistry protocol. A, As a negative control, primary 
antibody was omitted from the immunolabeing protocol to examine potential non-specific 
binding of secondary antibody to tissue. Sections from the same 1 week tissue that exhibited the 
strongest immunolabeling for TRPV1 were used for this negative control. B, As a positive 
control, choline acetyltransferase (ChAT) protein exhibits specific binding in distinctive layers of 
the IPL. This marker, associated with cholinergic amacrine cells, exhibits a uniform level of 
expression across all timepoints and treatments. 
 
amacrine cells form connections with RGCs. Our staining labeled these synaptic layers (Figure 
3.6B), as seen in other studies (Kang et al., 2004; Feng et al., 2006; Samuel et al., 2011). 
 Dendritic MAP2 protein levels exhibited a transient increase in fluorescence in 
microbead tissue from 4 days to 3 weeks (Figure 3.7). We observed localization of MAP2 
protein in the inner plexiform layer of the retina, as seen previously (Okabe et al., 1989; Seki et 
al., 2003; Vugler et al., 2008). Postsynaptic protein PSD-95 exhibited a similar trend in 
fluorescence, which also peaked at 3 weeks before decreasing (Figure 3.8). We observed 
localization of PSD-95 protein in the inner plexiform layer of the retina, as seen previously 
(Grunert et al., 2002; Stevens et al., 2007). Fluorescent intensity was quantified and averaged 
across IPL tissue area for both MAP2 and PSD-95 (Figure 3.9). 
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Figure 3.7. Dendritic MAP2 protein levels transiently increase following IOP elevation. Vertical 
sections of C57 mouse retinas immuno-labeled for dendritic MAP2 protein. MAP2 intensity 
transiently increases in retinas from microbead-injected eyes, especially in the IPL synaptic layer 
containing the dendrites of RGCs. IPL: inner plexiform layer. 
 
The MAP2 microbead:saline fluorescent intensity ratio was significantly increased at the 
1-week timepoint (p = 0.012; Figure 3.9A). This ratio remained elevated at 3 weeks, though this 
timepoint was not significantly elevated. At 5 and 7 weeks, the MAP2 ratio decreased and was 
not significantly different from unity. Similarly, the PSD-95 microbead:saline fluorescent 
intensity ratio increased from 4 days to 1-week and 3-week timepoints (Figure 3.9B). This ratio 
returned to levels near unity at 5- and 7-week timepoints. Similar to MAP2, the 1-week 
timepoint was significantly elevated above unity (p = 0.05). In the case of both MAP2 and PSD-
95, elevation of protein expression in the IPL was transient. This transient nature matches well 
with the changes seen in TRPV1 expression in tissue from the same animals (Figures 3.4 and 
3.5). 
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Colocalization of TRPV1 with postsynaptic protein PSD-95 
 TRPV1 and postsynaptic protein PSD-95 both exhibit transient increases in intensity 
levels (Figures 3.5 and 3.9B). This transient increase coincides, as is apparent in co-labeling of 
the two proteins in sections (Figure 3.10). Using orthogonal views across several serial optical 
sections of this co-labeled tissue, it appears that TRPV1 protein exhibits an increase in 
colocalization with PSD-95 after 1 week of IOP elevation (Figure 3.11). This increase in 
colocalization was diminished at 5 weeks, though some examples of overlapping TRPV1 and 
PSD-95 puncta are still apparent (Figure 3.11, arrows). 
 
 
Figure 3.8. Postsynaptic PSD-95 protein levels transiently increase following IOP elevation. 
Vertical sections of C57 mouse retinas immuno-labeled for postsynaptic PSD-95 protein. PSD-
95 intensity transiently increases in retinas from microbead-injected eyes, especially in the IPL 
synaptic layer containing the dendrites of RGCs. IPL: inner plexiform layer. 
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Figure 3.9. Quantification of PSD-95 and MAP2 protein levels in the inner plexiform layer. Red 
dashed line indicates equal levels of protein expression between eyes, where microbead:saline 
ratio equals one. A, Ratio of fluorescent intensity (microbead:saline) of immunolabeled MAP2 in 
sections of vertical retinal tissue. * = 0.012, n = 3-5 animals per group. B, Ratio of fluorescent 
intensity (microbead:saline) of immunolabeled PSD-95 in sections of vertical retinal tissue. * = 
0.05, n = 3-5 animals per timepoint. 
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Figure 3.10. Ocular hypertension transiently increases TRPV1 and PSD-95 protein in inner 
plexiform layer. Vertical retinal sections from C57 mouse eyes labeled for TRPV1 (red) and 
postsynaptic protein PSD-95 (green). Eyes were injected with microbeads (bottom row) to 
elevate IOP or saline (top row) as a control.  
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Figure 3.11. Ocular hypertension transiently increases proximity of TRPV1 and PSD-95 
proteins. Micrographs of inner plexiform layer from vertical sections through C57 mouse retina. 
Eyes were injected with microbeads (bottom row) to elevate IOP or saline (top row) as a control. 
Orthogonal views (at side and bottom of each micrograph) represent serial stacks compiled 
across tissue depth at each yellow line. X-axis line represents orthogonal image below microgaph 
and Y-axis line represents orthogonal image at side of micrograph. Arrowheads represent TRPV1 
(red) and PSD-95 (green) puncta in close apposition with each other (yellow). 
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Discussion 
Within the CNS, it is apparent that TRPV1 expression in neurons is affected by injurious 
stressors and pathology. Increases in TRPV1 protein were observed in lingual nerve injury 
(Biggs et al., 2007), chronic constriction injury (Kanai et al., 2005), and gentamicin-induced 
ototoxicity (Ishibashi et al., 2009). In human tissue, increases in TRPV1 protein levels were 
found in aged and photoaged skin and its associated nerve fibers (Lee et al., 2009), as well as in 
tissue collected from patients with traumatic and diabetic neuropathy (Facer et al., 2007). 
Within the retina, changes in TRPV1 protein levels have been observed accompanying 
elevated IOP in vivo. DBA/2 mice often exhibit gradual IOP elevation with age, which is 
followed by progressive degeneration of RGCs (John et al., 1998; Inman et al., 2006). In aged 
DBA/2 mice with elevated pressure, qualitative analysis of retinal immunolabeling indicated an 
apparent increase in TRPV1 localization to the inner plexiform layer (Sappington et al., 2009). In 
contrast, a model of retinal ischemia induced by high intraocular pressure saw whole retinal 
levels of TRPV1 decrease (Nucci et al., 2007b). This study used a transient, nonphysiological 
IOP (120 mmHg for 45 minutes), which is a much more robust insult than the gradual elevations 
(pressures of 17.7 and 21.8 mmHg) seen in the DBA/2 study (Nucci et al. 2007; Sappington et al. 
2009). Though these studies affect TRPV1 protein levels in opposite directions, they both 
indicate that IOP likely influences TRPV1 protein levels in the retina.  
Using our model of microbead-induced IOP elevation, we were able to determine how 
increased pressure affected TRPV1 levels and localization. Our studies of Trpv1 mRNA levels 
indicated no significant changes in the ratio between microbead- and saline-injected eyes. We 
did, however, see TRPV1 protein levels increase transiently at 1 week following microbead 
injection, and this effect was significant within the inner plexiform layer upon quantification. 
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Although not statistically significant, qualitative assessment indicates that TRPV1 protein levels 
transiently increased across most layers of the retina. It therefore may be the case that this 
transient increase is biologically, but not statistically, significant. This discrepancy between 
mRNA and protein expression could be due to when mRNA levels were measured (10 days 
versus 7 days for protein) and that any increase in Trpv1 mRNA had already returned to baseline. 
Our Trpv1 qPCR results are consistent with an early and transient increase in TRPV1 protein 
after injury. To confirm this, future studies should focus on earlier timepoints to determine how 
soon after microbead injection Trpv1 mRNA increases. The pressure elevation for this cohort of 
animals was also lower and less consistent than it was for cohorts used in other experiments, so 
this study could be improved with earlier timepoints and with mice exhibiting robust, consistent 
IOP elevation following microbead injection. 
Following IOP elevation, we also observed a transient increase in postsynaptic protein 
PSD-95 in the inner plexiform layer at 1 week post-injection. Other studies in the rodent retina 
have seen similar transient increases in PSD-95 following injury. In rat retina following optic 
nerve injury, an initial reduction in PSD-95 levels was observed 1 day after injury, followed by a 
transient increase (above control levels) that peaked at 7 days (Li et al., 2012). This pattern was 
observed in both mRNA and protein levels from whole retinal tissue. In another study using a 
model of rat sciatic nerve injury, an initial decrease in PSD-95 protein was also observed 6 hours 
after crush, which was sustained before levels rebounded at 1 week and increased above basal 
levels at 2 and 4 weeks (Gao et al., 2008). Similar to these injury studies, our results seem to 
indicate a transient increase in PSD-95 expression in response to IOP-induced stress. It is known 
that PSD-95 is required for activity-dependent synapse stabilization (Ehrlich et al., 2007), so 
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upregulation of the protein at synaptic sites may help stabilize syanpses that are in the process of 
being compromised. 
Similar to TRPV1 and PSD-95 expression, we observed a significant elevation in MAP2 
levels in the inner plexiform layer 1 week after microbead injection. The initial decrease in 
MAP2 expression at 4 days post-injection may coincide with compromised RGC activity due to 
the stressor of IOP elevation, as loss of MAP2 is an early indicator of neuronal injury (Akulinin 
and Dahlstrom, 2003; Huh et al., 2003). In a rodent model of focal cerebral ischemia, it was 
observed that most neurons progressively lost MAP2 immostaining, however some neurons in 
the central ischemic core exhibited increased MAP2 staining (Dawson and Hallenbeck, 1996). 
Maintenance of dendrites is activity-dependent (Lin and Koleske, 2010), and neuronal 
depolarization is known to increase dendritic MAP2 levels and association with microtubules 
(Roberts et al., 1998; Vaillant et al., 2002). We hypothesize that RGCs may respond to stressors 
by boosting activity (Ward et al., 2014), which may explain the rebound and increase in MAP2 
levels observed at our 1 week timepoint. Evidence of dendritic remodeling has been observed in 
neurodegenerative diseases including ALS, AD, and glaucoma (Karpati et al., 1988; Arendt et 
al., 1995; Baloyannis, 2009; Liu et al., 2011). Likewise, in studies examining cortical tissue 
damaged by ischemia, increased MAP2 staining observed in peri-lesional areas is thought to 
indicate compensatory restructuring in neurons that survive the insult (Bidmon et al., 1998; Li et 
al., 1998; Adkins-Muir and Jones, 2003). 
 Our co-labeling studies with TRPV1 and PSD-95 indicated that levels of both proteins 
increased transiently following IOP elevation. Based on studies of pre-embedding immunogold 
labeling of TRPV1 in hippocampus and extended amygdala, it appears that TRPV1 may exhibit 
perisynaptic expression rather than labeling associated directly with the postsynaptic density 
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(Puente et al., 2011; Puente et al., 2014). Qualitatively, our co-labeling data indicate that at 1 
week post-injection, TRPV1 and PSD-95 appear to be more closely associated with each other. 
Though we would have liked to pursue similar studies with MAP2, species cross-reactivity 
between our primary antibodies prevented us from colabeling our sections with both TRPV1 and 
MAP2. Despite this experimental limitation, we are able to conclude that TRPV1, MAP2, and 
PSD-95 all exhibit a transient increase in protein level within the IPL following 1 week of IOP 
elevation. It is important to note that these are simply changes in protein level, and our MAP2 
and PSD-95 results do not necessarily provide information about what is happening to the 
dendritic structures themselves. 
Our working hypothesis is that TRPV1 functions as an intrinsic stress responder that 
slows down RGC degeneration by increasing excitatory activity at RGC synapses. In the DBA/2 
mouse model of glaucoma, RGCs experiencing degeneration regularly exhibit dendrites with 
decreased complexity that lack higher-order branching, an indication of dendritic pruning 
(Jakobs et al., 2005). Likewise, it is known that synaptic activity is a crucial factor in long-term 
synapse maintenance (Lin and Koleske, 2010). Increased TRPV1 activity at RGC synapses may 
counter the dendritic pruning seen in glaucoma, as retention of synapses requires maintenance of 
synaptic activity. Our study and others have shown that eyes with elevated IOP exhibit increased 
levels of TRPV1 in the inner plexiform layer of the retina (Sappington et al., 2009), supporting 
the idea of increased synapse potentiation in response to stress. The inner plexiform layer 
includes extensive synaptic connections between RGC dendrites and bipolar cells, so the 
increases in TRPV1, PSD-95, and MAP2 that we observed in this layer may be part of a stress 
response to stabilize dendritic and synaptic structures in response to elevated IOP. 
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CHAPTER 4 
 
TRPV1 INFLUENCES RETINAL GANGLION CELL DENDRITIC COMPLEXITY 
 
Introduction 
 Within the CNS, it is well understood that TRPV1 modulates synaptic transmission in a 
multitude of neuronal systems (Marsch et al., 2007; Gibson et al., 2008; Li et al., 2008; Chavez 
et al., 2010; Grueter et al., 2010; Bennion et al., 2011). Previous studies have used subcellular 
localization techniques to show that TRPV1 may exert such modulatory effects in dendritic and 
perisynaptic structures (Puente et al., 2011; Puente et al., 2014). In vitro cultures of RGCs 
indicate an expression of TRPV1 throughout neurites (Sappington et al., 2009), and our studies 
in Chapter 3 demonstrate that TRPV1 may localize to RGC dendrites in vivo (Figures 3.3, 3.9, 
3.10). Intriguingly, following microbead-induced IOP elevation, temporal changes in TRPV1 
and in dendritic and synaptic protein levels within the inner plexiform layer exhibited similar 
dynamics (Figures 3.4 and 3.8), consistent with a synaptic modulatory role of TRPV1. 
 We have demonstrated in Chapter 2 that TRPV1 promotes RGC survival following IOP 
elevation in vivo (Ward et al., 2014), so it is important to consider how our knowledge of TRPV1 
expression and localization pairs with this function. Having observed a putative increase in 
dendritic TRPV1 expression, it is possible that TRPV1 exerts its effects at the synapse to help 
RGCs respond to stress and survive. It is worthwhile to examine prospective mechanisms such as 
this one because previous work has demonstrated that merely preventing RGC apoptosis does 
not also prevent degenerative progression. For example, deleting the Bax pro-apoptosis gene 
does not prevent glaucomatous axonopathy despite successfully protecting the RGC soma from 
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death (Libby et al., 2005). It is apparent from this result that the response of the RGC to insult 
will involve signal integration between dendrites, soma, and axon, as well as interactions with 
the cell’s synaptic contacts (Morquette and Di Polo, 2008). 
 Our hypothesis is that TRPV1 in the dendrites may influence overall RGC survival by 
modulating synaptic activity of RGCs in the retina. If TRPV1 can help prevent dendritic 
retraction, loss of synaptic connections, and reduction in synaptic activity in response to stress, 
RGCs would stand a better chance of surviving. In line with this hypothesis, it is believed that 
many CNS neurons have an intrinsic tuning ability with respect to their firing rates, and that they 
use this tuning as a method for homeostatic synaptic plasticity. Neurons involved in excitatory 
synapses are known to monitor their own activity, and in turn modify synaptic strength at their 
dendrites (Ibata et al., 2008; Turrigiano, 2008; Lee, 2012). This process appears to involve 
trafficking of glutamatergic receptors to or from synaptic sites (Turrigiano, 2008). Such 
mechanisms have already been demonstrated to involve Ca
2+
-permeable AMPA and NMDA 
receptors, and may be partially regulated by Ca
2+
 signaling in dendrites (Yu and Goda, 2009; 
Lee, 2012). 
It has already been hypothesized that this homeostatic synaptic plasticity is used in 
periods of elevated plasticity, such as recovery of neuronal function following injury (Lee, 
2012). In support of this hypothesis, it is known that Ca
2+
-permeable AMPA receptors are 
upregulated in neurons and their synaptic sites in models of neuronal insult and injury (Liu et al., 
2006; Spaethling et al., 2008). TRPV1 may similarly be upregulated in dendritic and perisynaptic 
sites following injury, making it a prime candidate for regulating homeostatic plasticity like other 
Ca
2+
-permeable channels. 
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 Given the potential for TRPV1 to influence synapse survival following injury, we 
examined whether Trpv1-/- influenced dendritic morphology following microbead-induced IOP 
elevation. If TRPV1 influences synaptic homeostasis as part of an RGC survival mechanism, 
then we would predict that Trpv1-/- mice will exhibit accelerated dendritic retraction following 
IOP elevation. We examined this by quantifying RGC morphometric data and conducting Sholl 
analyses of dendrite complexity in C57 and Trpv1-/- mice after 2 and 4 weeks of IOP elevation. 
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Materials and Methods 
Intracellular labeling of RGCs 
 Young C57 and Trpv1-/- mice (1 month) received injections of microbeads to elevate 
IOP for either ~2 or ~4 weeks (durations ranged from 12-15 days and 25-28 days, respectively) 
as described previously (Sappington et al., 2010). All procedures and IOP measurement methods 
followed those described in Chapter 2 Methods. In preparation for intracellular labeling of 
RGCs, mice were sacrificed by cervical dislocation followed by decapitation. Eyes were 
enucleated and dissected in oxygenated AMES media (Sigma) to remove the retina, which was 
then manually cleared of vitreous. Retinas were hemisected and transferred to a 0.5 mL enzyme 
solution containing hyaluronidase (300 units) and collagenase (120 units) to remove any 
remaining vitreous (Schmidt and Kofuji, 2011). This solution was placed in a dark oxygenated 
chamber and gently rocked for 10 minutes. Retinal halves were transferred to a holding chamber 
containing oxygenated AMES media for a minimum of 15 minutes. Retinal halves were placed 
RGC-side up in a recording chamber mounted on the stage of an Olympus BX50W1 upright 
fluorescent microscope (Olympus America) enclosed by a Faraday cage. The recording chamber 
was perfused with fresh oxygenated AMES at a rate of 2 mL/min. 
Borosilicate glass microelectrodes with a resistance of 5-10 MOhms were pulled on a p-
97 Flaming/Brown puller (Sutter Instruments, Sarasota, FL) and filled with a solution containing 
(in mM) K-gluconate (130), KCl (10), HEPES (10), MgCl2 (2), EGTA (1), Na2ATP (2), and 
NaGTP (0.3). For intracellular labeling, 1% Lucifer Yellow (LY, lithium salt; Life Technologies, 
Grand Island, NY) was also included in the internal solution. These microelectrodes were placed 
against select RGC somas using light positive pressure to clear the inner limiting membrane 
found on the surface of the retina. Gentle suction was then applied to form a gigaohm seal with 
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the RGC. Next, stronger bursts of rapid suction were applied to rupture the plasma membrane 
and gain access to the cell while keeping the cell intact. The result was a whole-cell patch clamp 
configuration. Cells were then labeled with LY via simple diffusion. Following a period of no 
less than 15 minutes, the microelectrode was gently removed, allowing the plasma membrane to 
reseal. This resulted in individual fluorescently-labeled RGCs. Within the retinal halves, multiple 
RGCs with non-overlapping dendritic trees were filled with LY. After labeling, retinal halves 
were transferred to 4% paraformaldehyde (PFA, Sigma) and incubated at 4ºC for a minimum of 
1 day. Retinas were rinsed in PBS, whole-mounted on a glass slide, and cover slipped for 
confocal imaging. 
 
Morphometric quantification of RGC dendrites 
Confocal images of LY-filled RGCs from whole-mounted retinal halves were imaged 
using an Olympus FV-1000 inverted confocal microscope. Only cells within the ganglion cell 
layer with obvious axons were imaged and analyzed in order to distinguish between RGCs and 
displaced amacrine cells. Using confocal images (0.101 mm
2
 per image), RGC somas and 
dendrites were traced manually using Adobe Illustrator CS5 (version 15.0.0, Adobe Systems 
Incorporated, San Jose, CA). 
 Somal area was measured using the ImageJ software (National Institutes of Health, 
Bethesda, MD) area quantification measurement tool (Figure 4.1A, yellow). Similarly, dendritic 
area was measured as the area bounded by a line connecting the outermost points of the dendrites 
around the edge of the dendritic tree (Figure 4.1A, cyan). Total dendritic length was measured in 
Image-Pro Plus (version 5.1.0.20, Media Cybernetics, Rockville, MD) using the dendrite length 
measurement routine (Figure 4.1A, black). Dendritic density was calculated by dividing a cell’s  
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Figure 4.1. Quantification of RGC dendritic morphometry. A, Confocal micrographs of Lucifer 
Yellow-filled RGCs were traced to measure several morphometric features, such as somal area 
(yellow), dendritic length (black), dendritic area (cyan), and total dendritic nodes (magenta). B, 
Dendritic morphology and complexity was examined by conducting Sholl analysis on RGC 
tracings. Concentric circles of increasing radius were centered about the RGC soma, and we 
quantified the number of dendritic intersections with each circle. 
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total dendritic length by its dendritic area. Nodes, or regions where dendrites branch, were 
manually quantified in Photoshop using the count tool (Figure 4.1A, magenta). Nodal density 
was calculated by dividing the number of nodes in the cell’s dendritic tree by the dendritic area. 
 
Sholl analysis of RGC dendrites 
 Sholl analysis of dendrites was conducted on images of traced dendrites using ImageJ 
software. Before analysis, the software was calibrated to the resolution of our original confocal 
images (1.614 pixels/µm) to guarantee correct measurements. Running the Sholl analysis routine 
in ImageJ, we drew a line from the center of the RGC soma to the farthest dendrite tip. 
Concentric circles were drawn around the soma, with a radius step size of 10 µm. This routine 
sampled the number of dendritic branches that intersected the circular rings drawn around the 
soma (Figure 4.1B). 
 
Statistical methods 
 Group averages were calculated and compared in SigmaPlot (version 11.1, SYSTAT) 
using two-sided t-tests for all data passing Shapiro-Wilk normality tests. For data that did not 
pass Shapiro-Wilk normality, non-parametric Mann-Whitney Rank Sum tests were used. Error as 
reported in text and on bar graphs represents mean ± SEM.  
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Results 
Microbead-induced IOP elevation in C57 and Trpv1-/- mice 
 To examine whether IOP elevation induces differential morphological changes between 
C57 and Trpv1-/- mice, we injected C57 and Trpv1-/- mouse eyes with microbeads (Sappington 
et al., 2010; Chen et al., 2011). A single microbead injection was used to elevate IOP in these 
mice for either 2 weeks or 4 weeks (Figure 4.2A). Cohorts of 2 week and 4 week mice were 
examined in both C57 and Trpv1-/- groups. 
 
 
Figure 4.2. Microbead-induced IOP elevation for animals used in morphological studies. A, 
Measurements of IOP taken from C57 and Trpv1-/- mice injected with microbeads. Baseline 
IOPs (Day 0) were measured prior to injection. Each animal received an injection of microbeads 
in one eye and an equivalent volume of saline in the contralateral eye. Each line represents IOPs 
of animals from cohorts sacrificed at either 2-week or 4-week timepoints following injection. B, 
Averaged IOP measurements for C57 and Trpv1-/- animals for all days post-injection (Days ≥1). 
*, p ≤ 0.009. 
 
Post-injection IOPs were averaged separately for C57 and Trpv1-/- mice (Figure 4.2B). 
For C57 mice, post-injection IOPs indicate an approximately 32% elevation in microbead-
injected eyes compared to contralateral eyes injected with an equivalent volume of saline. 
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Likewise, Trpv1-/- mice also exhibited an approximately 32% elevation in microbead-injected 
eyes compared to saline-injected eyes. This IOP elevation was statistically significant for both 
C57 (p = 0.009) and Trpv1-/- mice (p = 0.007). No difference in IOP was observed between 
genotypes for microbead- or saline-injected eyes (p > 0.998). 
 
Morphometric analysis of RGCs from C57 and Trpv1-/- mice 
 Following either 2 or 4 weeks of IOP elevation, retinas were collected from C57 and 
Trpv1-/- mouse eyes to conduct morphometric analysis of RGCs. Micrographs were created for 
Lucifer Yellow-filled RGCs, and tracings of cell somas and dendrites were produced. 
Micrographs and tracings were gathered for filled cells from C57 (Figures 4.3 and 4.4, 
respectively) and Trpv1-/- mice (Figures 4.5 and 4.6, respectively). Both C57 and Trpv1-/- mice 
exhibited a variety of morphological subtypes with respect to dendritic structure, consistent with 
the known diversity of RGC subtypes (Coombs et al., 2006). At least 20 filled RGCs were used 
in analysis from each cohort studied (n = 20-39 RGCs per cohort). 
 RGC somal area ranged from 148.42 ± 11.75 to 178.95 ± 25.94 µm
2
 across all groups, 
which matches with data previously published from mouse studies (Coombs et al., 2006). For 
comparisons made within each genotype (C57 vs. Trpv1-/-) and within treatment group 
(microbead injected vs. saline injected), no significant differences were observed in RGC somal 
area (Figure 4.7A). RGC dendritic area ranged from 33,197 ± 3,171 to 51,594 ± 8,167 µm
2
 
across all groups, which was similar to measurements reported previously (Coombs et al., 2006; 
Mazzoni et al., 2008). No significant differences in area were observed due to genotype or 
microbead injection (Figure 4.7B). Total RGC dendritic length ranged from 2,015.7 ± 159.8 to 
2,557.6 ± 272.8 µm across all groups, indicating a wide variety across RGC subtypes, as has  
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Figure 4.3. Lucifer Yellow-filled RGCs from C57 mice. Confocal micrographs from C57 mouse 
retinas of RGCs filled with Lucifer Yellow exhibit a variety of morphological subtypes. 
Micrographs were obtained from C57 mice following either 2 or 4 weeks of microbead-induced 
pressure elevation and were used for measurements and calculations of morphometric data. 
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Figure 4.4. Traced C57 mouse RGCs used for morphometric measurements. Examples of 
tracings generated from Lucifer Yellow-filled RGCs from C57 mice. Tracings indicate RGC 
dendrites (black), soma (yellow), and axon (red). Measurements of soma area, dendritic area, 
dendritic length, and dendritic nodes were derived from these tracings.  
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been observed previously (Coombs et al., 2006; Mazzoni et al., 2008). Significant differences in 
total dendritic length were observed between 4-week saline-injected mice from C57 and Trpv1-/- 
cohorts (p = 0.042, Figure 4.7C). These comparisons were no longer significant when dendritic 
length was normalized to dendritic area to calculate dendritic density, which ranged from 57.6 ± 
2.9 to 66.1 ± 4.3 nm
-1
 (Figure 4.7D). 
 Total dendritic nodes, which are points where dendrites branch, ranged in number from 
31.4 ± 2.2 to 48.5 ± 5.2 nodes across all groups, similar to counts reported previously (Mazzoni 
et al., 2008). Significant differences in total dendritic nodes were observed between 4-week 
saline-injected mice from C57 and Trpv1-/- cohorts (p = 0.008, Figure 4.7E). These comparisons 
were no longer significant when total dendritic node counts were normalized to dendritic area to 
calculate dendritic nodal density, which ranged from 9.46 x 10
-4
 ± 9.1 x 10
-5
 to 1.27 x 10
-3
 ± 1.5 
x 10
-4
 nodes/µm
2
 (Figure 4.7F). 
 
Sholl analysis of RGCs from C57 and Trpv1-/- mice 
 All RGCs used in morphometric analyses were used for subsequent Sholl analysis to 
examine branching complexity at consecutive 10 µm distance increments from the RGC soma. 
RGCs from mice sacrificed 2 weeks post-injection exhibited peak dendritic complexity 
approximately 70 µm away from their somas (Figure 4.8A). Trpv1-/- mice appeared to exhibit 
decreased complexity compared to C57 mice at this distance. For both C57 and Trpv1-/- animals, 
it did not appear that there was an effect of microbead injection on dendritic branching. RGCs 
from mice sacrificed 4 weeks post-injection all exhibited a peak dendritic complexity 
approximately 70-80 µm from their somas (Figure 4.8B). Trpv1-/- mice again appeared to  
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Figure 4.5. Lucifer Yellow-filled RGCs from Trpv1-/- mice. Confocal micrographs from Trpv1-
/- mouse retinas of RGCs filled with Lucifer Yellow exhibit a variety of morphological subtypes. 
Micrographs were obtained from Trpv1-/- mice following either 2 or 4 weeks of microbead-
induced pressure elevation and were used for measurements and calculations of morphometric 
data.  
111 
 
 
Figure 4.6. Traced Trpv1-/- mouse RGCs used for morphometric measurements. Examples of 
tracings generated from Lucifer Yellow-filled RGCs from Trpv1-/- mice. Tracings indicate RGC 
dendrites (black), soma (yellow), and axon (red). Measurements of soma area, dendritic area, 
dendritic length, and dendritic nodes were derived from these tracings. 
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exhibit decreased complexity compared to C57 mice at this radius. These animals also did not 
appear to exhibit an effect of microbead injection on dendritic branching. 
 Comparisons between groups (Figure 4.9) indicated that all significant comparisons arose 
from genotype (C57 versus Trpv1-/-) and not from treatment (saline-injected eye vs. microbead-
injected eye). At 2 weeks post-injection (Figure 4.9A), significant differences (p ≤ 0.05, n ≤ 40 
RGCs for each group compared) existed between RGCs from microbead-injected C57 and 
microbead-injected Trpv1-/- mice. At both 40 and 60 µm away from the RGC soma, the number 
of dendritic intersections for Trpv1-/- was reduced by 16% compared to C57. At 4 weeks post-
injection (Figure 4.9B), significant differences existed between RGCs (n ≤ 28 for each group 
compared) from microbead-injected C57 and microbead-injected Trpv1-/- mice at 50 µm (p ≤ 
0.05), 60 µm (p ≤ 0.01), 70 µm (p ≤ 0.001), 80 µm (p ≤ 0.05). Compared to C57, the number of 
intersections of Trpv1-/- RGCs in these groups was reduced by 24% at 50 µm, 27% at 60 µm, 
29% at 70 µm, and 28% at 80 µm. Only one 4 week saline-injected C57 and saline-injected 
Trpv1-/- comparison was significant, and this was at a distance of 90 µm from the soma (Figure 
4.9B). Compared to C57, the number of intersections of Trpv1-/- RGCs in this group were 
reduced by 31% (p ≤ 0.05, n ≤ 28 RGCs for each group compared).  
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Figure 4.7. Quantification of RGC morphometry. Morphometric measurements of Lucifer 
Yellow-filled RGCs were conducted following either 2 or 4 weeks of microbead-induced IOP 
elevation. Changes in morphology were examined by quantifying the following metrics: A, soma 
area; B, dendritic area; C, total dendritic length, * p ≤ 0.05; D, dendritic density (dendritic length 
normalized to dendritic area); E, total dendritic nodes, * p ≤ 0.05; F, dendritic nodal density 
(total dendritic nodes normalized to dendritic area).  
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Figure 4.8. Sholl analysis of C57 and Trpv1-/- RGC dendrites. Number of intersections of 
Lucifer Yellow-filled RGC dendrites with concentric rings drawn about the cell soma (see Figure 
4.1 for schematic). Quantifications were conducted for C57 and Trpv1-/- animals following 
either A, 2 weeks or B, 4 weeks of microbead-induced IOP elevation. 
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Figure 4.9. Trpv1-/- affects dendritic complexity as determined by Sholl analysis. Number of 
intersections of Lucifer Yellow-filled RGCs were quantified for Figure 4.8 and presented as 
averages for 9 consecutive radii that encompassed the greatest number of intersections. Averaged 
number of intersections were determined for cohorts of C57 and Trpv1-/- mice exposed to 
elevated pressure for A, 2 weeks or B, 4 weeks. *, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001.  
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Discussion 
 Reduced synaptic connectivity as well as dendritic retraction and abnormalities are 
common features of neurodegenerative diseases (Lin and Koleske, 2010). These degenerative 
alterations are observed in neurons from patients or models of Parkinson’s disease (Solis et al., 
2007), Alzheimer’s disease (Flood, 1991; Hanks and Flood, 1991; Moolman et al., 2004), and 
Huntington’s disease (Spires et al., 2004). These changes are also a feature in glaucomatous 
degeneration, as determined in a variety of species: human (Pavlidis et al., 2003),  primate 
(Weber et al., 1998), feline (Shou et al., 2003), and mouse (Jakobs et al., 2005). Understanding 
how and when dendritic retraction fits into the pathophysiology of glaucoma is an active area of 
research that is informed by our knowledge from other neurodegenerative diseases (Morquette 
and Di Polo, 2008). Knowledge of synaptic dynamics during disease will aid in determining 
therapeutic windows to rescue challenged neurons. For example, in Alzheimer’s disease, it is 
known that decline in memory and cognition is strongly correlated with synapse and dendrite 
loss, a degenerative feature that precedes actual cell death (Terry et al., 1991; Falke et al., 2003; 
Lin and Koleske, 2010). Therefore, in diseases like glaucoma, it may be important to focus on 
preservation of RGC synapses if dysfunctioning cells are to be rescued. Given the importance of 
TRPV1 in RGC survival, we hypothesized that TRPV1 may be imporant in slowing retraction of 
RGC dendrites following IOP elevation. 
 Our studies addressed this hypothesis by conducting morphometric analyses of C57 and 
Trpv1-/- mouse RGCs after 2 and 4 weeks of IOP elevation. These analyses indicated no 
changesbetween RGCs from saline- and microbead-injected eyes as measured by somal area, 
dendritic area, total dendritic length, dendritic density, total dendritic nodes, and dendritic nodal 
density (Figure 4.7). When considering only saline-injected retinas from 4 week cohorts, RGCs 
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from Trpv1-/- mice exhibited a significant reduction in total dendritic length and total dendritic 
nodes (Figure 4.7C,E) when compared to those from C57 mice. We did not expect to see such an 
alteration between this groups, which indicates that genotype may affect RGC dendritic 
morphometry. It is possible that Trpv1-/- animals simply possess RGCs with different 
morphometric properties; however, we would expect to see a difference in the 2 week animals as 
well, which we do not. Although unlikely, it cannot be ruled out that the act of injection itself 
causes alterations in RGC dendrites. To completely rule this possibility out, we would need to 
supplement these studies with C57 and Trpv1-/- animals that are naïve with respect to injection. 
Another consideration is that between all groups compared, the number of cells measured 
for each group ranged from 20-39 RGCs. Although several different methods of classifying RGC 
subtypes have been proposed (Sun et al., 2002; Badea and Nathans, 2004; Kong et al., 2005), it 
is estimated that at minimum 14 distinct subtypes of RGCs exist in the mouse retina (Coombs et 
al., 2006). Morphometric data collected from each of these subtypes indicate an appreciable 
variety in size, shape, and complexity of dendritic trees across all subtypes. Although RGCs 
were chosen for Lucifer Yellow filling with no prior knowledge of subtype, it is possible that 
certain subtypes were over- or underrepresented in our data. This seems especially possible given 
our relatively low sample size (n = 20-39 RGCs) compared to the number of RGC subtypes (a 
minimum of 14 proposed). In an effort to account for some of this variability, we normalized 
total dendritic length and total dendritic node counts to the dendritic area of each cell to calculate 
dendritic density and dendritic node density, respectively. When comparing the same groups 
using this normalized data, we discovered no statistically significant differences (Figure 4.7D,F). 
 To examine dendritic complexity, we conducted Sholl analysis (Sholl, 1953) on the same 
RGCs from which we collected morphometric data. This analytical method simply provides 
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information regarding the number of dendritic branches relative to distance from a neuron’s 
soma (Milosevic and Ristanovic, 2007). At both 2 (Figure 4.8A) and 4 weeks (Figure 4.8B), it 
appears that there is a genotypic difference in complexity as determined by the peak point of the 
curve. These curves seem to suggest that Trpv1-/- animals possess RGCs that are less complex 
regardless of their exposure to elevated IOP. Curves from Trpv1-/- mice 2 weeks after treatment 
indicate instances of RGCs with relatively long dendrites (extending beyond 400 µm from the 
RGC soma). Of note, these lengthy dendrites exist in Trpv1-/- retinas from both saline- and 
microbead-injected eyes, indicating that this is not an effect of treatment. Few RGCs actually 
contributed to these extended components of the Trpv1-/- curves, as can be observed by the 
associated error bars for those data points. Data points from the furthest locations on the curves 
have no error bars, as they represent measurements from a singular RGC. Although the tail end 
of these Trpv1-/- curves are influenced by a few RGCs, it is possible that this is a real effect and 
not simply due to an insufficient sampling of RGCs subtypes across all experimental groups. 
These extensive dendrites are only seen in Trpv1-/- animals regardless of treatment, so the 
absence of TRPV1 may disrupt regulation of proper dendritic structure in RGCs. 
It is known that TRPV1 activation can result in neuronal growth cone retraction, so it is 
possible that Trpv1-/- animals are unable to properly regulate necessary dendritic retraction 
(Goswami et al., 2007). This disruption of retraction may then result in a set of RGCs that exhibit 
more expansive dendritic trees. This effect is more apparent in the 2-week Trpv1-/- animals (both 
saline and microbead), and is only marginally apparent in 4-week Trpv1-/- animals (microbead 
only). It is possible that this could be a short-lived effect seen as an injury response to the 
injection, which would explain why it occurs in both saline and microbead groups. To see if this 
is the case, dendrites of RGCs from mice naïve to injection would need to be examined as well. 
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Statistically significant differences were observed only between phenotypes (C57 versus 
Trpv1-/-), and occurred at multiple distances in both 2- (Figure 4.9A) and 4-week (Figure 4.9B) 
groups of RGCs. The common feature between our morphometric data (Figure 4.8) and Sholl 
analysis (Figure 4.9) is that Trpv1-/- dendrite elaboration is reduced compared to C57 dendrites, 
regardless of whether they were exposed to IOP elevation. Without consideration of potential 
effects of genotype, our analyses indicate no significant differences between RGCs from saline- 
and microbead-injected eyes at either 2 or 4 weeks post-injection. Currently, only one study has 
systematically, but not exhaustively characterized RGC dendritic morphology using a microbead 
occlusion model similar to ours (Della Santina et al., 2013). This study used similar durations of 
IOP elevation (15 and 30 days compared to our 12-15 and 25-28 days, respectively), and these 
elevations were of a comparable magnitude. Their analyses indicated no significant retraction at 
2 weeks. At 4 weeks, they note that a subset of OFF transient RGCs exhibited significant 
dendritic retraction, whereas OFF sustained and ON sustained cells did not. This study is not 
exhaustive, as these were the only RGC subtypes examined, but it does suggest a context for our 
data. 
First, we may benefit from examining RGCs from longer durations of IOP elevation. 
Second, it appears that not all subtypes of RGCs exhibit retraction at early timepoints, a 
possibility that has been supported by work in a laser-induced model of ocular hypertension 
(Feng et al., 2013). Currently, we do not have enough data to analyze changes by subtype, so we 
may consider either collecting more measurements at 2 and 4 weeks or extending the duration of 
IOP elevation to cause a more robust effect. Due to these limitations, we are unable to presently 
determine whether TRPV1 aids in the preservation of RGC synapses and dendrites exposed to 
elevated IOP. 
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CHAPTER 5 
 
SUMMARY 
 
Purpose of studies 
 The objective of these studies was to examine how cation channel TRPV1 (transient 
receptor potential vanilloid-1) modulates neurodegeneration of RGCs in glaucoma. From prior 
studies in vitro, we knew that TRPV1 activity influences RGC survival in response to pressure 
(Sappington et al., 2009). Using this knowledge, we decided to examine the influence of TRPV1 
in glaucomatous degeneration of RGCs in an in vivo model of glaucoma. We hypothesized that 
TRPV1 functions to counteract RGC dysfunction through enhancing synaptic activity at RGC 
dendrites. This hypothesis was addressed using three specific aims: 
 Aim 1. Determine influence of TRPV1 on RGC degenerative outcomes. 
 Aim 2. Determine compartmental nature of TRPV1 response in RGCs. 
 Aim 3. Establish relevance of TRPV1 in survival of RGC dendrites. 
 
Determining the influence of TRPV1 on RGC degenerative outcomes 
 Examining the responses of C57 and Trpv1-/- animals to microbead-induced IOP 
elevation allowed us to better understand the function of TRPV1 during glaucomatous 
pathology. As expected, microbead injection reduced transport of CTB to the LGN and SC in 
C57 mice; however, deficits in transport were significantly worse in Trpv1-/- mice. As expected, 
examination of RGC axons in sections of the optic nerve revealed that microbead injection 
caused a reduction in axon counts and density. This reduction was significantly worse in Trpv1-/- 
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mice than in C57 mice. When looking at the retina, RGC soma counts were not significantly 
reduced for C57 mice as a result of microbead injection. Trpv1-/- mice, however, did exhibit a 
reduction in RGC somas in the retina, but this reduction was limited to the nasal quadrant of the 
retina, as has been seen in previous studies (Lambert et al., 2011). Examination of 
phosphorylated neurofilaments in these retinas revealed somatodendritic accumulations in RGCs 
that reflected dysfunction in transport along their axons. In terms of phosphorylated 
neurofilaments (pNF), Trpv1-/- mice exhibited more RGCs with pNF accumulation than did C57 
mice. 
 Future directions for this part of the project could entail trying to examine if these 
changes occur in a progressive model of disease that exhibits gradual IOP elevation. For 
instance, this might involve backcrossing Trpv1-/- mice onto a DBA/2 genetic background. The 
same outcome measures could be used in terms of assessing pathology. Unfortunately, 
conducting the backcrossing would take a long time and the development of a large colony 
would be necessary to assess several ages of animals. It is also possible that the inherent 
variability of the DBA/2 progression might make results difficult to interpret. We saw variability 
in progression across all mice used in our microbead-induced study (see data distributions in 
Figures 2.10A, 2.12A), so it is likely the variability would be even greater using animals on the 
DBA/2 background.  
 
Determining the compartmental nature of the TRPV1 response in RGCs 
 To determine if elevated IOP changes TRPV1 levels at both the mRNA and protein level, 
we conducted qPCR and immunohistochemistry experiments. These experiments were 
conducted using C57 mice injected with microbeads, which were sacrificed at several different 
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timepoints. We did not observe a significant change in Trpv1 transcript levels following IOP 
elevation; however, it is possible that we missed the window of time in which levels of this 
transcript would be increased. This possibility is especially informed by our immunolabeling 
data, in which we saw early increases in TRPV1. By quantifying fluorescent intensity within 
cellular and synaptic layers of the retina, we were able to determine that TRPV1 protein levels 
are increased in the inner plexiform layer following one week of pressure elevation. This 
increase was transient and was not significant for later timepoints. The inner plexiform layer 
includes the dendrites of RGCs, so it is possible that this increase in protein in the inner 
plexiform layer was due to increased expression of TRPV1 in the RGC dendrites. 
 Our immunolabeling data also indicated increased protein levels of synaptic protein PSD-
95 and dendritic protein MAP2 following 1 week of pressure elevation. Similar to our 
immunolabeling data for TRPV1, these increases were transient. It is possible that the 
upregulation of these proteins is a compensatory response following the stressor of increased 
IOP. In our examination of TRPV1 and PSD-95 expression together in the inner plexiform layer, 
we observed that both proteins exhibited increased levels after 1 week of IOP elevation, and that 
they also appeared to become more closely associated with each other. This increased 
colocalization was transient, and decreased again after the 1 week timepoint. 
 Future directions for this part of the project would entail conducting high resolution 
imaging of RGC dendritic synapses and dendritic structures. Confocal microscopy does not 
possess the resolving power to determine if TRPV1 is truly localized within dendritic and 
synaptic structures, so we would have to use other imaging techniques. Based on studies that 
demonstrated perisynaptic localization of TRPV1 (Puente et al., 2011; Puente et al., 2014), it 
would be worth seeing if TRPV1 might modulate RGC synaptic activity in a similar location. 
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These studies would require using pre-embedding immunogold labeling for TRPV1 and imaging 
by high resolution electron microscopy. While those studies might take longer to develop, a 
quicker, but less sensitive method to examine this would involve collecting synaptosomes from 
retinal tissue and conducting Western blots for TRPV1. Although this technique provides no 
spatial or cell-type specific information, it could implicate TRPV1 as a synaptic protein in the 
mouse retina. 
 
Establishing the relevance of TRPV1 in survival of RGC dendrites 
 Based on our knowledge that knockout of Trpv1 makes microbead-induced pathology 
worse, and that TRPV1 protein levels increase in the inner plexiform layer after IOP elevation, 
we wanted to examine if TRPV1 might exhibit a stress response role within the dendrites. If 
TRPV1 is important in maintenance of dendrites during stress, we would expect to see that, in 
comparison to C57 mice, Trpv1-/- mice exhibit an accelerated retraction of dendrites following 
microbead injection. To examine this, we elevated pressure in C57 and Trpv1-/- mice by 
microbead injection, which was sustained for either 2 weeks or 4 weeks. After collecting retinas 
from these mice, we used Lucifer Yellow to fill randomly-selected RGCs for our analyses. This 
allowed for imaging of RGCs for morphometric analysis of dendritic structures. 
 It seems that we used timepoints that may have been too early to detect dendritic changes, 
as we saw no difference in any measure when comparing between saline and microbead eyes. 
However, when we compared RGCs from C57 to those from Trpv1-/-, we saw that there may be 
a difference in dendritic elaboration based on genotype. These differences were most noticeable 
by Sholl analysis, in which we could see differences in peak dendritic complexity between C57 
and Trpv1-/- animals at both 2 and 4 week timepoints. It is intriguing to consider the idea that 
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during development, TRPV1 may play a role in determining the branching complexity profile of 
RGCs. 
 Future directions for this part of the project would entail collecting morphological 
information from many more RGCs. This would allow for a more complete analysis that could 
be broken down based on RGC subtype. This may be an important approach, as other studies 
indicate that RGC subtype plays a role in determining vulnerability of specific RGCs to 
progression of dendritic retraction (Della Santina et al., 2013; Feng et al., 2013). In a study that 
used timepoints similar to ours, it was observed that only one of the three RGC subtypes they 
examined actually exhibited dendritic retraction in response to microbead-induced IOP elevation 
(Della Santina et al., 2013). This issue of subtype specificity may not be as prominent if we 
elected to consider longer periods of pressure elevation. Considering that we have chosen 
timepoints at which we see no difference between saline and microbead groups, we will need to 
consider using longer durations of IOP elevation. 
 
Potential mechanisms of TRPV1 in RGC survival 
 Based on our results, we speculate that TRPV1 is involved in signaling and synaptic 
plasticity mechanisms that may be responsible for helping RGCs survive in response to stress. 
Future studies will need to focus upon how this occurs, and there are numerous possibilities for 
investigation. In order to understand the mechanism of TRPV1 in RGC survival, it will be 
important to understand what is activating TRPV1 in vivo during glaucomatous stress. Upstream 
of the receptor itself, we must understand what in the disease environment is activating TRPV1, 
and whether or not levels of this activator change during the course of the disease. TRPV1 can be 
activated by endogenous ligands, including various endocannabinoids, which can additionally 
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influence neuronal survival due to their activity at cannabinoid receptors. An important study 
would examine how TRPV1-activating endocannabinoid levels change within the retina 
following elevation of IOP by microbead injection. 
 To understand TRPV1-related mechanisms central to this set of studies, it will also be 
important to understand what is occurring subsequent to TRPV1 activation. We have proposed 
that TRPV1 activation helps maintain synaptic activity in response to elevated stress. Using 
electrophysiology, we have already determined that in C57 mice, RGCs exhibit increased 
spontaneous firing rates following IOP elevation (Ward et al., 2014). This increase in firing rate 
was not present in RGCs from Trpv1-/- animals. These electrophysiology results seem to indicate 
that Trpv1-/- causes RGCs to lose an intrinsic mechanism that increases RGC excitation in 
response to glaucomatous stress. 
Currently, we are unsure what could cause this increase in RGC excitation, but it could 
potentially be mediated by alterations in endocannabinoid levels. Previous studies have indicated 
that enhancing synaptic activity, even in injured or degenerating neurons, helps these neurons 
survive (Corredor and Goldberg, 2009). Even following optic nerve axotomy in rats, stimulating 
retinal neurons using a trans-corneal electrode increased RGC survival in vivo (Morimoto et al., 
2005). If we apply this knowledge to the data presented here as well as from our Trpv1-/- 
electrophysiology, we may begin to understand mechanistically how TRPV1 influences RGC 
survival. To tie this activity to neuronal survival, it would be interesting to see if pro-survival 
signaling, such as CREB signaling, is increased as a result of this TRPV1 activation (Brunet et 
al., 2001). It is possible that TRPV1-mediated enhancement of RGC activity could lead to both 
maintenance of synaptic structures, as well as changes in pro-survival signaling downstream of 
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channel activation. It will be important to further explore the mechanism of how TRPV1 
influences RGC survival, as this may help in developing treatment strategies for glaucoma. 
  
TRPV1-based interventions for neurodegeneration in glaucoma 
 In the past, glaucoma treatment has been focused on preventing progression, but recently, 
research has focused on targeting mechanisms that may allow for early interventions and 
preventative measures. One of the mechanisms that has garnered much attention is cannabinoid 
signaling, which can exhibit overlap with TRPV1 signaling due to common ligands (Pertwee, 
2006). It has been demonstrated that the cannabinoid system is at least one component of the 
response to toxic and traumatic insults within the CNS (Mechoulam and Shohami, 2007; Fowler 
et al., 2010). Using the knowledge that both TRPV1 and cannabinoid signaling can enhance 
survival in response to neuronal stress, it seems practical to develop interventions that exploit 
both mechanisms. 
 The cannabinoid system is perhaps best known because the active component of 
marijuana, Δ9-tetrahydrocannabinol (THC), activates cannabinoid receptors CB1 and CB2 
(Pertwee, 2008). However, these receptors can also be activated by endocannabinoids, which are 
cannabinoid receptor ligands that are produced endogenously. This means that, aside from their 
activation by exogenous compounds like THC, these receptors and their endogenous ligands 
must constitute a system used for particular purposes by cells. Within the CNS, we know that 
endocannabinoids can mediate aspects of synaptic plasticity and neuroprotection (Yazulla, 
2008). These mechanisms involve retrograde suppression of neurotransmitter release from 
presynaptic terminals. From a mechanistic standpoint, this suppression occurs when dendrites of 
a postsynaptic neuron become depolarized, leading to a Ca
2+
-dependent release of 
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endocannabinoid, which then diffuses to CB1 receptors on the presynaptic neuron to reduce 
neurotransmitter release (Ohno-Shosaku et al., 2001; Wilson and Nicoll, 2001). This suppression 
of neurotransmitter release can be neuroprotective, as in the case of injurious situations in which 
excessive glutamate release can cause excitotoxicity (van der Stelt et al., 2002). 
 Neuroprotective potential is not the only factor that makes cannabinoids an interesting 
focus for future glaucoma therapeutics—cannabinoids have long been linked to reduction in IOP 
(Green, 1979). It is apparent that cannabinoids are responsible for IOP reduction by locally 
acting upon CB1 receptors in the eye (Song and Slowey, 2000). Exogenous cannabinoids can 
influence IOP; however, endocannabinoids known to exist within human ocular tissue as well 
(Chen et al., 2005; Matias et al., 2006), and the cannabinoid receptors at which they act are also 
found there (Porcella et al., 2000; Stamer et al., 2001), indicating potential mechanisms for 
endogenous regulation of IOP. In glaucoma, IOP is the leading modifiable risk factor (Sommer, 
1989; Gordon et al., 2002), and lowering IOP is the most common form of treatment thus far 
(Heijl et al., 2002). Therapeutic interventions that target the endocannabinoid system are 
therefore encouraging because they may influence neuroprotective mechanisms in two different 
ways: directly by affecting endocannabinoid signaling related to neuronal survival and indirectly 
by lowering IOP. 
 Such neuroprotective intervention should also consider the knowledge of TRPV1 
presented here. Our studies indicate that in response to elevated IOP, TRPV1 helps counter 
degenerative progression in a mouse model of glaucoma. Therefore, in considering therapeutic 
mechanisms, it would make sense to use compounds that modulate both endocannabinoid and 
TRPV1 signaling. This idea has been supported by in vivo work in the rat retina, which suggests 
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that by activating cannabinoid and TRPV1 receptors, anandamide protects against RGC death by 
high IOP (Nucci et al., 2007b). 
One difficulty in targeting the endocannabinoid system is that endocannabinoids are 
hydrolyzed in vivo, and thus their bioavailability may be a concern during treatment. For 
example, anandamide is hydrolyzed by fatty acid amide hydrolase (FAAH), which breaks the 
amide bond and produces arachidonic acid and ethanolamine (Cravatt et al., 1996; Giang and 
Cravatt, 1997; McKinney and Cravatt, 2005). This degradation by FAAH occurs within cells, 
thus a controversial hypothesis has been asserted that there exists an undiscovered anandamide 
membrane transporter (AMT) which clears anandamide from the extracellular space (Bari et al., 
2006; Nucci et al., 2008). An AMT may exist, as various compounds have been demonstrated to 
function as anandamide uptake inhibitors (Beltramo et al., 1997; Melck et al., 1999; Rakhshan et 
al., 2000; Di Marzo et al., 2002). Interestingly, some of these compounds that block anandamide 
uptake can also interact with FAAH, cannabinoid receptors, or TRPV1. One intriguing 
anandamide inhibitor is olvanil, which is formed as the condensation product of the polar head of 
capsaicin and oleic acid (Melck et al., 1999). In one study, olvanil in propylene glycol was 
applied to the eye via topical administration, causing significant IOP reduction in rabbits (Laine 
et al., 2001). In addition to inhibiting anandamide uptake, olvanil activates both TRPV1 and 
cannabinoid receptors (Di Marzo et al., 1998; Appendino et al., 2005). Olvanil may therefore 
have potential in glaucoma treatment due to several reasons: (1) inhibiting anandamide uptake 
allows for longer activation of cannabinoid receptors by anandamide, (2) olvanil itself can 
activate both cannabinoid receptors and TRPV1, and (3) olvanil has been demonstrated to reduce 
IOP. By both reducing IOP and targeting endogenous TRPV1- and CB1 receptor-mediated 
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neuroprotective signaling, olvanil and similar compounds may offer a more comprehensive way 
of addressing glaucoma. 
Tailoring new and more effective intervention strategies for glaucoma patients is crucial. 
Currently, intervention strategies are focused on later stages of the disease; however, during 
these stages, vision loss is occurring and many RGCs have already died (Figure 5.1, red box). 
This is not an ideal stage for intervention, as RGCs cannot be restored following apoptosis; 
therefore, interventions at this stage can only hope to preserve what vision is left. For 
interventions to be most effective, they must work to preempt vision loss by protecting RGCs 
during earlier stages of dysfunction (Figure 5.1, green bracket). In these studies, we have 
demonstrated that TRPV1 is a component of an early response to glaucomatous stress, and that it 
is important for RGC survival in response to this stress. Based on these results, it would make 
sense to develop treatments for use at an early stage and that would, at least in part, target 
TRPV1 signaling. 
In developing early intervention, more animal studies would need to be conducted using 
compounds such as olvanil. It would be important to see what the bioavailability of this drug 
would be within ocular tissue following topical administration to the eye, as this is a concern 
(Jarvinen et al., 2002). If the drug cannot act on TRPV1 and cannabinoid receptors within the 
retina, then it will be no more effective than current eye drop therapies that simply lower IOP. 
However, if in addition to lowering IOP, olvanil is also able to act on TRPV1 and cannabinoid 
receptors in the retina, this drug may provide a more comprehensive protection to RGCs under 
stress. 
Should animal models demonstrate that olvanil or similar drugs are more effective than 
drugs that simply lower IOP, developing interventions for human patients could be a possibility. 
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Such intervention will likely need to be developed with a subset of patients who haven’t 
demonstrated vision loss, but are at risk for glaucoma due to elevated pressure. These patients  
 
Figure 5.1. Timeline of degeneration and potential for intervention. Using results from animal 
models of glaucoma, a timeline for pathological features of disease progression can be 
approximated. In glaucoma, loss of vision is due to death of RGCs, which cannot be replaced; 
therefore, interventions that occur later in disease progression can only focus upon preventing 
further RGC death. Unfortunately, current interventions usually occur once disease progression 
is in later stages (red box). Our work with TRPV1 indicates that modulating early protective 
responses to disease-related stressors may prolong RGC survival. This timeline from animal 
models suggests that there is a window of time (green bracket) in which early intervention would 
be beneficial, allowing RGCs to maintain function instead of progressing to apoptosis. 
 
Figure altered and used with permission from DJ Calkins. Timeline events adapted from Calkins 
(2012). 
 
would be able to benefit from TRPV1- and cannabinoid receptor-mediated mechanisms of 
neuroprotection that may rely upon retention of synapses in the retina. Patients who are at later 
stages of disease would already exhibit retraction and loss of synapses in the retina, and thus 
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would not be able to benefit as robustly from such mechanisms of intervention (Figure 5.1, red 
box). It is important to realize that the success of any TRPV1-mediated treatment strategy would 
likely need to be early in disease progression, and thus continued research to identify early-stage 
disease biomarkers will be especially crucial for identifying patients who might benefit from 
such treatment. This knowledge, combined with screening for elevated IOP, would help identify 
at-risk patients who might benefit from early-stage intervention that, in part, would take 
advantage of TRPV1-mediated signaling. 
 
Conclusions 
 Altogether, these studies indicate that TRPV1 helps counter degenerative progression in 
an in vivo mouse model of glaucoma. In our microbead model, Trpv1-/- animals exhibited 
accelerated pathology across all of our degenerative outcome measures when compared to C57 
animals. In examining C57 retinas exposed to various durations of elevated IOP, we observed 
transient increases of TRPV1 in a synaptic layer of the retina associated with RGC dendritic 
structures. This may suggest that these channels modulate synaptic activity soon after insult from 
elevated IOP. Although we were not able to determine if Trpv1-/- animals exhibited accelerated 
dendritic pathology in our morphometric analyses, we did observe an interesting genotypic effect 
on RGC dendritic complexity, regardless of IOP exposure. As a whole, these results suggest that 
TRPV1, and TRP channels in general, may be relevant for modulation of neurodegenerative 
disease progression, and that these channels may be useful therapeutic targets. 
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